<html lang="en" class="pb-page js" data-request-id="94d67ae42361628a-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d67ae42361628a-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/bGE4BfNVlWICSHjpzKsgm5RmQwZeqJQGtIWqclBBN1aNKZ_3-zYUL927A0nMFlWRTgwZRGCyYKY3TYbb7bwQEg=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d67ae42361628a-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.4925014600456369"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Breast Cancer|Treatments in Oncology">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Hematology/Oncology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2028485","title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","category":"Research","type":"Original Article","topics":"Breast Cancer|Treatments in Oncology","specialties":"Hematology/Oncology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-04-22T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Breast Cancer|Treatments in Oncology\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2028485","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Visual Abstract","title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","doi":"10.1056/NEJMdo005998","issueDate":"2021-04-22T00:00Z","age":"6Months-1990","isFree":"y","topics":"Breast Cancer|Treatments in Oncology","viewType":"Full","specialties":"Hematology/Oncology"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d67ae42361628a-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer"><meta name="dc.Creator" content="Aditya Bardia"><meta name="dc.Creator" content="Sara A. Hurvitz"><meta name="dc.Creator" content="Sara M. Tolaney"><meta name="dc.Creator" content="Delphine Loirat"><meta name="dc.Creator" content="Kevin Punie"><meta name="dc.Creator" content="Mafalda Oliveira"><meta name="dc.Creator" content="Adam Brufsky"><meta name="dc.Creator" content="Sagar D. Sardesai"><meta name="dc.Creator" content="Kevin Kalinsky"><meta name="dc.Creator" content="Amelia B. Zelnak"><meta name="dc.Creator" content="Robert Weaver"><meta name="dc.Creator" content="Tiffany Traina"><meta name="dc.Creator" content="Florence Dalenc"><meta name="dc.Creator" content="Philippe Aftimos"><meta name="dc.Creator" content="Filipa Lynce"><meta name="dc.Creator" content="Sami Diab"><meta name="dc.Creator" content="Javier Cortés"><meta name="dc.Creator" content="Joyce O’Shaughnessy"><meta name="dc.Creator" content="Véronique Diéras"><meta name="dc.Creator" content="Cristiano Ferrario"><meta name="dc.Creator" content="Peter Schmid"><meta name="dc.Creator" content="Lisa A. Carey"><meta name="dc.Creator" content="Luca Gianni"><meta name="dc.Creator" content="Martine J. Piccart"><meta name="dc.Creator" content="Sibylle Loibl"><meta name="dc.Creator" content="David M. Goldenberg"><meta name="dc.Creator" content="Quan Hong"><meta name="dc.Creator" content="Martin S. Olivo"><meta name="dc.Creator" content="Loretta M. Itri"><meta name="dc.Creator" content="Hope S. Rugo"><meta name="dc.Description" content="Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell-surfac..."><meta name="Description" content="Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell-surfac..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-04-22"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2028485"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202104223841608"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYoa2028485"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2028485">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2028485">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2028485">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer | NEJM">
        <meta property="og:title" content="Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2028485">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/ee77e7c3-1723-41ef-9d69-b22a916bc846/nejmoa2028485_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/ee77e7c3-1723-41ef-9d69-b22a916bc846/nejmoa2028485_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab
govitecan is an antibody–drug conjugate composed of an antibody targeting the human
trophoblast cell-surfac...">
        <meta name="twitter:description" content="Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab
govitecan is an antibody–drug conjugate composed of an antibody targeting the human
trophoblast cell-surfac...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2019">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2028485">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2028485">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2028485;wgroup:string:MMS NextGen Website Group;issue:issue:doi\:10.1056/nejm_2021.384.issue-16;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="preconnect" href="https://use.typekit.net"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2028485" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2028485" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2028485" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2028485" class="inputDoi"><input type="hidden" value="A. Bardia and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;384:1529-1541" class="inputCitation"><input type="hidden" value="04-21-2021" class="inputEPubDate"><input type="hidden" value="April 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup modal-lg"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d67ae42361628a-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Aditya</span> <span property="familyName">Bardia</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sara A.</span> <span property="familyName">Hurvitz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sara M.</span> <span property="familyName">Tolaney</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Delphine</span> <span property="familyName">Loirat</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kevin</span> <span property="familyName">Punie</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mafalda</span> <span property="familyName">Oliveira</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Adam</span> <span property="familyName">Brufsky</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+23</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sagar D.</span> <span property="familyName">Sardesai</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kevin</span> <span property="familyName">Kalinsky</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Amelia B.</span> <span property="familyName">Zelnak</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert</span> <span property="familyName">Weaver</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tiffany</span> <span property="familyName">Traina</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Florence</span> <span property="familyName">Dalenc</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Philippe</span> <span property="familyName">Aftimos</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Filipa</span> <span property="familyName">Lynce</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sami</span> <span property="familyName">Diab</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Javier</span> <span property="familyName">Cortés</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joyce</span> <span property="familyName">O’Shaughnessy</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Véronique</span> <span property="familyName">Diéras</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Cristiano</span> <span property="familyName">Ferrario</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter</span> <span property="familyName">Schmid</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lisa A.</span> <span property="familyName">Carey</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Luca</span> <span property="familyName">Gianni</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Martine J.</span> <span property="familyName">Piccart</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sibylle</span> <span property="familyName">Loibl</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">David M.</span> <span property="familyName">Goldenberg</span>, <span property="honorificSuffix">Sc.D., M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Quan</span> <span property="familyName">Hong</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Martin S.</span> <span property="familyName">Olivo</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Loretta M.</span> <span property="familyName">Itri</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Hope S.</span> <span property="familyName">Rugo</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the ASCENT Clinical Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-23</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">April 21, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">384</span></span>:<span property="pageStart">1529</span>-<span property="pageEnd">1541</span></div><div class="doi">DOI: 10.1056/NEJMoa2028485</div><div class="core-enumeration"><a href="/toc/nejm/384/16"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">384</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">16</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DAditya%2BBardia%252C%2BSara%2BA.%2BHurvitz%252C%2BSara%2BM.%2BTolaney%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D16%26contentID%3D10.1056%252FNEJMoa2028485%26title%3DSacituzumab%2BGovitecan%2Bin%2BMetastatic%2BTriple-Negative%2BBreast%2BCancer%26publicationDate%3D04%252F22%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2028485" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DAditya%2BBardia%252C%2BSara%2BA.%2BHurvitz%252C%2BSara%2BM.%2BTolaney%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D16%26contentID%3D10.1056%252FNEJMoa2028485%26title%3DSacituzumab%2BGovitecan%2Bin%2BMetastatic%2BTriple-Negative%2BBreast%2BCancer%26publicationDate%3D04%252F22%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/4e5a85fb-98b0-4183-908c-a5cee9203a50/nejmoa2028485.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2028485.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028485" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2028485" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2028485.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this randomized, phase 3 trial, we evaluated sacituzumab govitecan as compared with single-agent chemotherapy of the physician’s choice (eribulin, vinorelbine, capecitabine, or gemcitabine) in patients with relapsed or refractory metastatic triple-negative breast cancer. The primary end point was progression-free survival (as determined by blinded independent central review) among patients without brain metastases.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 468 patients without brain metastases were randomly assigned to receive sacituzumab govitecan (235 patients) or chemotherapy (233 patients). The median age was 54 years; all the patients had previous use of taxanes. The median progression-free survival was 5.6 months (95% confidence interval [CI], 4.3 to 6.3; 166 events) with sacituzumab govitecan and 1.7 months (95% CI, 1.5 to 2.6; 150 events) with chemotherapy (hazard ratio for disease progression or death, 0.41; 95% CI, 0.32 to 0.52; P&lt;0.001). The median overall survival was 12.1 months (95% CI, 10.7 to 14.0) with sacituzumab govitecan and 6.7 months (95% CI, 5.8 to 7.7) with chemotherapy (hazard ratio for death, 0.48; 95% CI, 0.38 to 0.59; P&lt;0.001). The percentage of patients with an objective response was 35% with sacituzumab govitecan and 5% with chemotherapy. The incidences of key treatment-related adverse events of grade 3 or higher were neutropenia (51% with sacituzumab govitecan and 33% with chemotherapy), leukopenia (10% and 5%), diarrhea (10% and &lt;1%), anemia (8% and 5%), and febrile neutropenia (6% and 2%). There were three deaths owing to adverse events in each group; no deaths were considered to be related to sacituzumab govitecan treatment.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer. Myelosuppression and diarrhea were more frequent with sacituzumab govitecan. (Funded by Immunomedics; ASCENT ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02574455" target="_blank">NCT02574455</a>; EudraCT number, <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003019-21" target="_blank">2017-003019-21</a>.)</div></section></section><div class="core-digital-object visual-abstract">
<div class="ng-page_separator pt-24"></div>
<div class="ng-do-media">
    <button data-toggle="modal" data-target="#doPopup" class="ng-do-media_btn" modal-size="lg"></button>
    <div data-ajaxurl="/do/10.1056/NEJMdo005998/full/?ajaxRequest=true" class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="#" class="ng-do-media_item-img-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005998" data-multimedia-filename="NEJMdo005998_600x400.jpg">
                <img src="/cms/asset/f78348ee-76b6-4cef-a30a-29cf0e9cd162/media/NEJMdo005998_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-visual"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/visual-abstract" class="ng-do-media_item-type-link">Visual Abstract</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="#" class="ng-do-media_item-title-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005998" data-multimedia-filename="NEJMdo005998_600x400.jpg">Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer</a>
            </h6>
        </div>
    </div>
</div>

</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Patients with metastatic triple-negative breast cancer (defined by a lack of tumor-cell expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 [HER2]) have poor survival outcomes.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2-1" href-manipulated="true">1,2</a></sup> Although immunotherapy has shown promising first-line clinical activity, single-agent chemotherapy remains standard for previously treated (beyond first-line) metastatic triple-negative breast cancer.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3 r4" id="body-ref-r4" href-manipulated="true">2-4</a></sup> However, chemotherapy is associated with low response rates and short progression-free survival.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6 r7 r8 r9" id="body-ref-r9-1" href-manipulated="true">5-9</a></sup></div><div role="paragraph">Sacituzumab govitecan is an antibody–drug conjugate composed of an antitrophoblast cell-surface antigen 2 (Trop-2) IgG1 kappa antibody coupled to SN-38, the active metabolite of irinotecan and a topoisomerase I inhibitor,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10" href-manipulated="true" aria-label="Reference 10">10</a></sup> through a proprietary hydrolyzable linker.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12" id="body-ref-r12-1" href-manipulated="true">11,12</a></sup> Trop-2 is a transmembrane calcium signal transducer that is highly expressed in multiple tumor types, including breast cancer (&gt;90%).<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14 r15" id="body-ref-r15" href-manipulated="true">13-15</a></sup> After administration, the anti–Trop-2 monoclonal antibody binds to Trop-2 expressed on the tumor-cell surface and allows for targeted delivery of SN-38 to tumor cells.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r16" id="body-ref-r16" href-manipulated="true">12,16</a></sup> Because free SN-38 is membrane-permeable, it may elicit antitumor effects in adjacent tumor cells (bystander effect) before internalization of the antibody–drug conjugate through hydrolysis of the linker or by intracellular SN-38 release after internalization.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r14 r17 r18 r19 r20" id="body-ref-r20" href-manipulated="true">12,14,17–20</a></sup></div><div role="paragraph">A phase 1–2, single-group, basket trial (IMMU-132-01) evaluated sacituzumab govitecan monotherapy in metastatic, epithelial cancers.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r22 r23" id="body-ref-r23-1" href-manipulated="true">21-23</a></sup> In the cohort of 108 patients with metastatic triple-negative breast cancer, an objective response rate of 33%, a median progression-free survival of 5.5 months, and a median overall survival of 13.0 months was observed with sacituzumab govitecan.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-2" href-manipulated="true" aria-label="Reference 23">23</a></sup> These results provided the basis for accelerated approval by the Food and Drug Administration (FDA) in April 2020, with full approval contingent on the results of the confirmatory phase 3 trial.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> Here we provide the primary results of the confirmatory phase 3 ASCENT trial, a global, open-label, randomized trial evaluating the efficacy and safety of sacituzumab govitecan as compared with chemotherapy of the physician’s choice (eribulin, vinorelbine, capecitabine, or gemcitabine) in patients with relapsed or refractory metastatic triple-negative breast cancer (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org).</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">We enrolled patients with metastatic triple-negative breast cancer that was relapsed or refractory to two or more previous standard chemotherapy regimens (no upper limit) for unresectable, locally advanced or metastatic disease; previous therapy had to include a taxane (for any indication). Patients had to have triple-negative breast cancer according to standard American Society of Clinical Oncology–College of American Pathologists criteria.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup> Patients with stable brain metastases for at least 4 weeks before treatment were eligible for the trial but were excluded from the primary end-point analysis. Additional details are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-2"><h3>Trial Design and Treatment</h3><div role="paragraph">Patients were randomly assigned in a 1:1 ratio to receive sacituzumab govitecan (Trodelvy; Immunomedics, a subsidiary of Gilead Sciences) at a dose of 10 mg per kilogram of body weight intravenously on days 1 and 8 of each 21-day cycle or single-agent chemotherapy as determined before randomization: eribulin (1.4 mg per square meter of body-surface area [North America] or 1.23 mg per square meter [Europe] intravenously on days 1 and 8 of a 21-day cycle), vinorelbine (25 mg per square meter intravenously on day 1 weekly), capecitabine (1000 to 1250 mg per square meter orally twice daily on days 1 to 14 of a 21-day cycle), or gemcitabine (800 to 1200 mg per square meter intravenously on days 1, 8, and 15 of a 28-day cycle). Patients were stratified at randomization according to the number of previous chemotherapy regimens for advanced disease (2 or 3 vs. &gt;3), the presence of known brain metastases at baseline (yes vs. no), and geographic region (North America vs. rest of the world). Treatment was continued until disease progression, unacceptable toxic effects, withdrawal from the trial, or death, whichever occurred first. No crossover to the sacituzumab govitecan group was allowed on progression with chemotherapy.</div><div role="paragraph">Polymorphisms in the gene encoding uridine diphosphate glucuronosyltransferase 1A1 (e.g., homozygosity for <i>UGT1A1*28</i>) are associated with SN-38 glucuronidation and an increased risk of hematologic toxic effects with sacituzumab govitecan.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r23" id="body-ref-r23-3" href-manipulated="true">18,23</a></sup> Therefore, inhibitors and inducers of <i>UGT1A1</i> were used with caution.</div></section><section id="sec-1-3"><h3>Trial Oversight</h3><div role="paragraph">The trial was approved by the institutional review board or ethics committee at each investigational site before initiation and was performed in accordance with the Declaration of Helsinki, International Council for Harmonisation guidelines for Good Clinical Practice, the FDA Code of Federal Regulations, national and local drug and data-protection laws, and other applicable regulatory requirements. All the patients provided written informed consent before enrollment.</div><div role="paragraph">The sponsor team, including former and current employees, designed and conducted the trial and gathered data in collaboration with the trial investigators. Trial oversight was provided by the trial steering committee and an independent data and safety monitoring committee. The data analysis was performed by Immunomedics, with statistical service rendered by Covance. The first author, with members of the steering committee and sponsor, guided the initial manuscript draft after an agreement to publish with editorial assistance from professional medical writers funded by the sponsor. The authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the <a href="#ap1">protocol</a> (available at NEJM.org). All drafts of the manuscript were reviewed and approved by the authors.</div></section><section id="sec-1-4"><h3>Assessments</h3><div role="paragraph">The primary end point was progression-free survival (as determined by blinded independent central review) among patients without known baseline brain metastases (measured by computed tomography [CT] or magnetic resonance imaging [MRI] according to Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup>). Screening for brain metastasis was not mandatory. This prespecified primary end point, approved by regulatory authorities, allowed for investigation of the clinical benefit of sacituzumab govitecan in patients with metastatic triple-negative breast cancer without the confounding effects of brain metastases, a poor prognostic factor. Progression-free survival among patients with brain metastases will be reported separately. Secondary end points included overall survival, progression-free survival (investigator assessment), objective response, and safety. Imaging (CT or MRI) was performed every 6 weeks for 36 weeks, then every 9 weeks thereafter, until disease progression leading to treatment discontinuation. Responses required confirmatory scans 4 to 6 weeks later. Patients were contacted every 4 weeks to assess survival during long-term follow-up.</div><div role="paragraph">Safety was evaluated in all treated patients according to the <i>Medical Dictionary for Regulatory Activities</i>, version 22.1, and the severity of adverse events was coded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Premedication for infusion reactions was recommended, antiemetics and supportive measures were allowed, and diarrhea was treated at its onset (details are provided in the Methods section in the <a href="#ap2">Supplementary Appendix</a>).</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">Anticipated enrollment was 488 patients, including patients with or without brain metastases at baseline, with a 15% cap for patients with brain metastases. The efficacy analyses involved the patients without brain metastases at baseline as well as the full trial population. Under the assumption of a hazard ratio for disease progression or death (sacituzumab govitecan vs. chemotherapy) of 0.667, 315 events of progression or death would provide an estimated 95% power to detect a significant between-group difference in progression-free survival in the primary efficacy population; the expected progression-free survival with sacituzumab govitecan was 4.5 months, as compared with 3 months with chemotherapy of the physician’s choice. To control for type I error at a two-sided alpha level of 0.05, a hierarchical testing procedure (gatekeeping) was implemented for testing progression-free and overall survival. On the unanimous recommendation of the data and safety monitoring committee, the trial was halted in March 2020, and the process to conduct a final analysis was initiated owing to compelling evidence of efficacy.</div><div role="paragraph">Progression-free survival was defined as the time from randomization until objective tumor progression or death or was censored at the last radiographic assessment for patients without progression or death. Progression-free survival, overall survival, and response duration were analyzed with the use of the Kaplan–Meier method, with medians and corresponding 95% confidence intervals determined according to the Brookmeyer and Crowley method with log–log transformation. The 95% confidence intervals were not adjusted for multiplicity and cannot be used to infer treatment effects. Treatment effect was compared with the use of a stratified log-rank test. Hazard ratios and their 95% confidence intervals were estimated with the use of a stratified Cox proportional-hazards model. The percentage of patients with an objective response was compared between the treatment groups with the use of the stratified Cochran–Mantel–Haenszel method. The same stratification factors that were used for the randomization were used in the stratified efficacy analyses.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patient Characteristics</h3><div role="paragraph">A total of 529 patients with triple-negative breast cancer were enrolled between November 2017 and September 2019 at 88 sites in seven countries and were randomly assigned in a 1:1 ratio to receive sacituzumab govitecan or single-agent chemotherapy. A total of 61 patients had brain metastases at baseline, and 468 patients had no evidence of brain metastases (primary trial population for the analysis of efficacy); 235 patients were assigned to receive sacituzumab govitecan and 233 patients to receive single-agent chemotherapy prespecified by the investigator (54% eribulin, 20% vinorelbine, 13% capecitabine, and 12% gemcitabine). A total of 32 patients who were assigned to receive chemotherapy received no trial drug (26 patients) or withdrew consent (6 patients) before treatment; these 32 patients are included in the efficacy analysis but not in the safety analyses.</div><div role="paragraph">Patients had a median age of 54 years (range, 27 to 82); previous treatments included taxanes (100%), anthracyclines (82%), carboplatin (66%), inhibitors of programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) (27%), and poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors (7%) (<a href="#t1">Table 1</a>). Patients had discontinued their previous treatment primarily because of progressive disease (78%); 3% had discontinued because of adverse events. Approximately 30% of the patients were not triple-negative at initial diagnosis, and this discordance between primary tumor staining and metastatic recurrence underscores the importance of obtaining biopsy samples at the time of recurrence. At the time of data cutoff (March 11, 2020), 15 of 235 patients (6%) continued to receive sacituzumab govitecan and 0 of 233 patients continued to receive chemotherapy (Fig. S2).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t1.jpg"><img src="/cms/10.1056/NEJMoa2028485/asset/15e27d35-9b19-41e1-b7f7-aa267bed8b26/assets/images/large/nejmoa2028485_t1.jpg" height="3307" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Sacituzumab Govitecan <br>(N=235)</th><th class="txxr-borders">Chemotherapy<br>(N=233)<a href="#t1fn2" role="doc-noteref">†</a></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Sex — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Female</td><td class="xxxx-borders">233 (99)</td><td class="xxxr-borders">233 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders">54 (29–82)</td><td class="xxxr-borders">53 (27–81)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">188 (80)</td><td class="xxxr-borders">181 (78)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">28 (12)</td><td class="xxxr-borders shading">28 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">9 (4)</td><td class="xxxr-borders">9 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other or not specified</td><td class="xxxx-borders shading">10 (4)</td><td class="xxxr-borders shading">15 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">ECOG performance-status score at screening — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">0</td><td class="xxxx-borders shading">108 (46)</td><td class="xxxr-borders shading">98 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">1</td><td class="xxxx-borders">127 (54)</td><td class="xxxr-borders">135 (58)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Germline <i>BRCA1</i> or <i>BRCA2</i> mutation status — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Negative</td><td class="xxxx-borders">133 (57)</td><td class="xxxr-borders">125 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Positive<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">16 (7)</td><td class="xxxr-borders shading">18 (8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Triple-negative breast cancer at initial diagnosis — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">165 (70)</td><td class="xxxr-borders shading">157 (67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">70 (30)</td><td class="xxxr-borders">76 (33)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time from diagnosis of metastatic disease to enrollment (range) — mo<a href="#t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">15.8 (0–202.9)</td><td class="xxxr-borders shading">15.2 (0–140.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Major tumor locations — no. (%)<a href="#t1fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Lung</td><td class="xxxx-borders shading">108 (46)</td><td class="xxxr-borders shading">97 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Liver</td><td class="xxxx-borders">98 (42)</td><td class="xxxr-borders">101 (43)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Axillary lymph nodes</td><td class="xxxx-borders shading">57 (24)</td><td class="xxxr-borders shading">73 (31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Bone<a href="#t1fn10" role="doc-noteref">§§</a></td><td class="xxxx-borders">48 (20)</td><td class="xxxr-borders">55 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median no. of previous anticancer regimens (range) <a href="#t1fn11" role="doc-noteref">¶¶</a></td><td class="xxxx-borders shading">3 (1–16)</td><td class="xxxr-borders shading">3 (1–12)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Previous chemotherapy regimens — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">2 or 3</td><td class="xxxx-borders shading">166 (71)</td><td class="xxxr-borders shading">164 (70)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&gt;3</td><td class="xxxx-borders">69 (29)</td><td class="xxxr-borders">69 (30)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Previous chemotherapy drugs — no. (%)<a href="#t1fn12" role="doc-noteref">‖‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Taxanes</td><td class="xxxx-borders">235 (100)</td><td class="xxxr-borders">233 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Anthracyclines</td><td class="xxxx-borders shading">191 (81)</td><td class="xxxr-borders shading">193 (83)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cyclophosphamide</td><td class="xxxx-borders">192 (82)</td><td class="xxxr-borders">192 (82)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Carboplatin</td><td class="xxxx-borders shading">147 (63)</td><td class="xxxr-borders shading">160 (69)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Capecitabine</td><td class="xxxx-borders">147 (63)</td><td class="xxxr-borders">159 (68)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Previous use of PARP inhibitors — no. (%)</td><td class="xxxx-borders shading">17 (7)</td><td class="xxxr-borders shading">18 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Previous use of PD-1 or PD-L1 inhibitors — no. (%)</td><td class="xbxx-borders">67 (29)</td><td class="xbxr-borders">60 (26)</td></tr></tbody></table></div><figcaption><div class="caption">Baseline Characteristics and Previous Treatment of Patients without Brain Metastases.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">PARP denotes poly(adenosine diphosphate–ribose) polymerase, PD-1 programmed death 1, and PD-L1 programmed death ligand 1.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">The chemotherapy group included patients randomly assigned to receive eribulin (126 patients), vinorelbine (47), capecitabine (31), and gemcitabine (29).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Race was reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating that the patient is fully active with no restrictions, 1 indicating that the patient is ambulatory and able to carry out work of a light or sedentary nature but restricted in physically strenuous activity, and higher numbers indicating increasing degrees of disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Patients who did not undergo <i>BRCA1</i> or <i>BRCA2</i> germline testing or who had inconclusive results are not included.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">Among the patients with <i>BRCA1</i> or <i>BRCA2</i> mutations at baseline, 10 of 16 (62%) in the sacituzumab govitecan group and 11 of 18 (61%) in the chemotherapy group had previously received PARP inhibitors.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">Patients whose initial diagnosis was hormone receptor–positive or human epidermal growth factor receptor 2–positive breast cancer had a median time from diagnosis of metastatic disease to enrollment of 22.5 months (range, 2.1 to 202.9) in the sacituzumab govitecan group and 21.2 months (range, 1.1 to 140.1) in the chemotherapy group.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t1fn8" role="paragraph">The time from diagnosis of metastatic disease is defined as number of days from the date of first diagnosis of metastasis to the date of trial entry divided by 30.4375.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="t1fn9" role="paragraph">Tumor locations were based on independent central review of target and nontarget lesions at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="t1fn10" role="paragraph">Patients with bone-only disease were not permitted in the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶¶</div><div id="t1fn11" role="paragraph">Anticancer regimens refer to any previous regimens for metastatic or locally advanced disease or in the neoadjuvant context that were used to treat an eligible patient with breast cancer. Previous therapy in the adjuvant context is excluded from this count.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖‖</div><div id="t1fn12" role="paragraph">Shown are most common chemotherapy drugs used. Taxanes include paclitaxel, nab-paclitaxel, and docetaxel. Anthracyclines include doxorubicin, daunorubicin, epirubicin, and different formulations of these agents.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy in Patients without Brain Metastases</h3><div role="paragraph">As of the March 11, 2020, data cutoff, the median follow-up time from patients’ randomization date was 17.7 months (range, 5.8 to 28.1). The median progression-free survival as determined by central review (primary end point) was 5.6 months (95% confidence interval [CI], 4.3 to 6.3) with sacituzumab govitecan and 1.7 months (95% CI, 1.5 to 2.6) with chemotherapy (hazard ratio for disease progression or death, 0.41; 95% CI, 0.32 to 0.52; P&lt;0.001) (<a href="#t2">Table 2</a> and <a href="#f1">Figure 1A</a>). Progression-free survival as determined by central review was consistent with investigator assessments (5.5 months with sacituzumab govitecan and 1.7 months with chemotherapy; hazard ratio for disease progression or death, 0.35; 95% CI, 0.28 to 0.44) (Fig. S3). The median overall survival was 12.1 months (95% CI, 10.7 to 14.0) with sacituzumab govitecan and 6.7 months (95% CI, 5.8 to 7.7) with chemotherapy (hazard ratio for death, 0.48; 95% CI, 0.38 to 0.59; P&lt;0.001) (<a href="#t2">Table 2</a> and <a href="#f1">Figure 1B</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028485_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028485_f1.jpg"><img src="/cms/10.1056/NEJMoa2028485/asset/ee77e7c3-1723-41ef-9d69-b22a916bc846/assets/images/large/nejmoa2028485_f1.jpg" height="2019" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Efficacy Results in Patients without Brain Metastases at Baseline and in the Full Population.</div><div class="notes"><div role="doc-footnote">Panels A and B show progression-free and overall survival, respectively, among patients without brain metastases. Progression-free survival was determined by blinded independent central review according to Response Evaluation Criteria in Solid Tumors, version 1.1. Panel C shows a waterfall plot of the best percent change in the sum of the diameters of target lesions in patients without brain metastases who had at least one response assessment by central review (212 patients in the sacituzumab govitecan group and 160 in the chemotherapy group). Asterisks at 0 denote patients who had no change from baseline in tumor size. Panel D shows progression-free survival among all randomly assigned patients (with or without brain metastases).</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t2.jpg"><img src="/cms/10.1056/NEJMoa2028485/asset/52f54318-9af0-4b91-9fc7-1699d6ddbfcd/assets/images/large/nejmoa2028485_t2.jpg" height="1533" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="2"><span>Patients without Brain Metastases</span></th><th class="txxr-borders" colspan="2"><span>Full Population<a href="#t2fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Sacituzumab Govitecan <br>(N=235)</th><th class="xxxx-borders">Chemotherapy<br>(N=233)</th><th class="xxxx-borders">Sacituzumab Govitecan <br>(N=267)</th><th class="xxxr-borders">Chemotherapy<br>(N=262)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median progression-free survival (95% CI) — mo</td><td class="xxxx-borders shading">5.6 (4.3−6.3)</td><td class="xxxx-borders shading">1.7 (1.5−2.6)</td><td class="xxxx-borders shading">4.8 (4.1–5.8)</td><td class="xxxr-borders shading">1.7 (1.5–2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hazard ratio for disease progression or death (95% CI)</td><td class="xxxx-borders">0.41 (0.32−0.52)<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.43 (0.35−0.54)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median overall survival (95% CI) — mo</td><td class="xxxx-borders shading">12.1 (10.7−14.0)</td><td class="xxxx-borders shading">6.7 (5.8−7.7)</td><td class="xxxx-borders shading">11.8 (10.5–13.8)</td><td class="xxxr-borders shading">6.9 (5.9–7.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hazard ratio for death (95% CI)</td><td class="xxxx-borders">0.48 (0.38−0.59)<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.51 (0.41–0.62)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Objective response — no. of patients (%)<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">82 (35)</td><td class="xxxx-borders shading">11 (5)</td><td class="xxxx-borders shading">83 (31)</td><td class="xxxr-borders shading">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response</td><td class="xxxx-borders">10 (4)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">10 (4)</td><td class="xxxr-borders">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Partial response</td><td class="xxxx-borders shading">72 (31)</td><td class="xxxx-borders shading">9 (4)</td><td class="xxxx-borders shading">73 (27)</td><td class="xxxr-borders shading">9 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Clinical benefit — no. of patients (%)<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">105 (45)</td><td class="xxxx-borders">20 (9)</td><td class="xxxx-borders">108 (40)</td><td class="xxxr-borders">21 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Stable disease — no. of patients (%)</td><td class="xxxx-borders shading">81 (34)</td><td class="xxxx-borders shading">62 (27)</td><td class="xxxx-borders shading">96 (36)</td><td class="xxxr-borders shading">71 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stable disease for ≥6 mo</td><td class="xxxx-borders">23 (10)</td><td class="xxxx-borders">9 (4)</td><td class="xxxx-borders">25 (9)</td><td class="xxxr-borders">10 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Progressive disease — no. of patients (%)</td><td class="xxxx-borders shading">54 (23)</td><td class="xxxx-borders shading">89 (38)</td><td class="xxxx-borders shading">65 (24)</td><td class="xxxr-borders shading">100 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Response could not be evaluated — no. of patients (%)<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">18 (8)</td><td class="xxxx-borders">71 (30)</td><td class="xxxx-borders">23 (9)</td><td class="xxxr-borders">80 (31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time to response (95% CI) — mo</td><td class="xxxx-borders shading">1.5 (0.7−10.6)</td><td class="xxxx-borders shading">1.5 (1.3−4.2)</td><td class="xxxx-borders shading">1.5 (0.7–10.6)</td><td class="xxxr-borders shading">1.5 (1.3−4.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xxxx-borders">6.3 (5.5−9.0)</td><td class="xxxx-borders">3.6 (2.8−NE)</td><td class="xxxx-borders">6.3 (5.5–9.0)</td><td class="xxxr-borders">3.6 (2.8–NE)</td></tr><tr data-type="row"><td class="xblx-borders hanging12 shading">Hazard ratio (95% CI)</td><td class="xbxx-borders shading" data-xml-align="center">0.39 (0.14−1.07)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Summary of Treatment Efficacy, as Determined by Independent Central Review.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">NE denotes could not be estimated.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The full population includes all randomly assigned patients (with and without brain metastases).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">P&lt;0.001.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">An objective response was defined as a complete response or partial response.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">Clinical benefit was defined as a complete response, a partial response, or stable disease with a duration of at least 6 months.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t2fn6" role="paragraph">Response could not be evaluated for a variety of reasons, including a lack of postbaseline images or unreadable images.</div></div></div></figcaption></figure></div><div role="paragraph">The progression-free survival benefit of sacituzumab govitecan over chemotherapy was consistently observed across all predefined subgroups (<a href="#f2">Figure 2</a>), including patients 65 years of age or older (median, 7.1 vs. 2.4 months), those with more than three previous therapies (5.6 vs. 2.5 months), those with previous use of PD-1 or PD-L1 inhibitors (4.2 vs. 1.6 months), those with triple-negative breast cancer at initial diagnosis (5.7 vs. 1.6 months), those without triple-negative breast cancer at initial diagnosis (4.6 vs. 2.3 months), and those with liver metastases (4.2 vs. 1.5 months). Subgroup analyses of median overall survival similarly favored sacituzumab govitecan over chemotherapy (Fig. S4).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028485_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028485_f2.jpg"><img src="/cms/10.1056/NEJMoa2028485/asset/e02a8b15-fcc3-4f89-812c-1bee96644cf7/assets/images/large/nejmoa2028485_f2.jpg" height="1808" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Subgroup Analysis of Progression-free Survival.</div><div class="notes"><div role="doc-footnote">NE denotes could not be evaluated, PD-1 programmed death 1, PD-L1 programmed death ligand 1, and TNBC triple-negative breast cancer.</div></div></figcaption></figure></div><div role="paragraph">The percentage of patients with an objective response was 35% with sacituzumab govitecan and 5% with chemotherapy (<a href="#t2">Table 2</a> and <a href="#f1">Figure 1C</a>). Clinical benefit was also noted in all subgroups evaluated (Fig. S5). The median duration of response was 6.3 months (95% CI, 5.5 to 9.0) with sacituzumab govitecan and 3.6 months (95% CI, 2.8 to could not be estimated) with chemotherapy (hazard ratio, 0.39; 95% CI, 0.14 to 1.07) (Fig. S6). The median time to response was 1.5 months (range, 0.7 to 10.6) with sacituzumab govitecan and 1.5 months (range, 1.3 to 4.2) with chemotherapy.</div></section><section id="sec-2-3"><h3>Efficacy in the Full Population</h3><div role="paragraph">Among all randomly assigned patients (with or without brain metastases), the median progression-free survival was 4.8 months (95% CI, 4.1 to 5.8) with sacituzumab govitecan and 1.7 months (95% CI, 1.5 to 2.5) with chemotherapy (hazard ratio for disease progression or death, 0.43; 95% CI, 0.35 to 0.54) (<a href="#t2">Table 2</a> and <a href="#f1">Figure 1D</a>). The median overall survival was 11.8 months (95% CI, 10.5 to 13.8) with sacituzumab govitecan and 6.9 months (95% CI, 5.9 to 7.7) with chemotherapy (hazard ratio, 0.51; 95% CI, 0.41 to 0.62) (Fig. S7).</div></section><section id="sec-2-4"><h3>Safety</h3><div role="paragraph">The safety population consisted of the 482 patients who received at least one treatment dose (258 in the sacituzumab govitecan group and 224 in the chemotherapy group). The median relative dose intensity with sacituzumab govitecan was 99.7%; patients received sacituzumab govitecan for a median of 4.4 months (maximum, 22.9 months). Overall, 99.6% of the patients in the sacituzumab govitecan group and 99.1% of those in the chemotherapy group received preinfusion or concomitant medication (see the Results section in the <a href="#ap2">Supplementary Appendix</a>).</div><div role="paragraph">The most common treatment-related adverse events of any grade were neutropenia (63% with sacituzumab govitecan and 43% with chemotherapy), diarrhea (59% and 12%), nausea (57% and 26%), alopecia (46% and 16%), fatigue (45% and 30%), and anemia (34% and 24%) (<a href="#t3">Table 3</a>). The most frequent treatment-related adverse events of grade 3 or higher were neutropenia (51% with sacituzumab govitecan and 33% with chemotherapy), leukopenia (10% and 5%), diarrhea (10% and &lt;1%), anemia (8% and 5%), and febrile neutropenia (6% and 2%). In the sacituzumab govitecan group, treatment-related adverse events involving rash of any grade (in 22 patients [9%] overall; 1 patient with a grade 3 event) and ocular toxic effects (in 12 patients [5%]; no patients with an event of grade &gt;1) occurred with low incidence, and no neuropathy of greater than grade 2 was observed. No grade 1 or 2 interstitial lung disease was reported, and grade 3 pneumonitis developed in 1 patient (see the Results section in the <a href="#ap2">Supplementary Appendix</a>). In the chemotherapy group, treatment-related adverse events involving rash of any grade (in 3 patients [1%] overall; 1 patient with a grade 3 event), ocular toxic effects (in 6 patients [3%]; no patients with an event of grade &gt;2), and neuropathy of greater than grade 2 (2 patients [1%]) occurred at low frequency, and no interstitial lung disease was reported.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t3.jpg"><img src="/cms/10.1056/NEJMoa2028485/asset/6ce73d92-7733-4624-9a38-cb5c94dd9130/assets/images/large/nejmoa2028485_t3.jpg" height="2426" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="3"><span>Sacituzumab Govitecan <br>(N=258)</span></th><th class="txxr-borders" colspan="3"><span>Chemotherapy<br>(N=224)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3</th><th class="xxxx-borders">Grade 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3</th><th class="xxxr-borders">Grade 4</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="6"><span><i>number of patients (percent)</i></span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">252 (98)</td><td class="xxxx-borders shading">117 (45)</td><td class="xxxx-borders shading">48 (19)</td><td class="xxxx-borders shading">192 (86)</td><td class="xxxx-borders shading">71 (32)</td><td class="xxxr-borders shading">33 (15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Hematologic event</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Neutropenia<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">163 (63)</td><td class="xxxx-borders shading">88 (34)</td><td class="xxxx-borders shading">44 (17)</td><td class="xxxx-borders shading">96 (43)</td><td class="xxxx-borders shading">45 (20)</td><td class="xxxr-borders shading">29 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Anemia<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">89 (34)</td><td class="xxxx-borders">20 (8)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">54 (24)</td><td class="xxxx-borders">11 (5)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Leukopenia<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">41 (16)</td><td class="xxxx-borders shading">23 (9)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxx-borders shading">25 (11)</td><td class="xxxx-borders shading">10 (4)</td><td class="xxxr-borders shading">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Thrombocytopenia<a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">14 (5)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">25 (11)</td><td class="xxxx-borders">3 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Febrile neutropenia</td><td class="xxxx-borders shading">15 (6)</td><td class="xxxx-borders shading">12 (5)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxx-borders shading">5 (2)</td><td class="xxxx-borders shading">4 (2)</td><td class="xxxr-borders shading">1 (&lt;1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Gastrointestinal event</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">153 (59)</td><td class="xxxx-borders shading">27 (10)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">27 (12)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">147 (57)</td><td class="xxxx-borders">6 (2)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">59 (26)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Vomiting</td><td class="xxxx-borders shading">75 (29)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">23 (10)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Constipation</td><td class="xxxx-borders">44 (17)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">32 (14)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders shading">29 (11)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">9 (4)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">General disorders and administration-site conditions</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">115 (45)</td><td class="xxxx-borders shading">8 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">68 (30)</td><td class="xxxx-borders shading">12 (5)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asthenia</td><td class="xxxx-borders">31 (12)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">23 (10)</td><td class="xxxx-borders">3 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Skin and subcutaneous disorders: alopecia<a href="#t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">119 (46)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">35 (16)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Metabolism and nutrition disorders: decreased appetite</td><td class="xxxx-borders">51 (20)</td><td class="xxxx-borders">4 (2)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">32 (14)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Nervous system disorders<a href="#t3fn7" role="doc-noteref">**</a><a href="#t3fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">64 (25)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">53 (24)</td><td class="xxxx-borders shading">5 (2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Respiratory, thoracic, and mediastinal disorders<a href="#t3fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">41 (16)</td><td class="xxxx-borders">5 (2)<a href="#t3fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">17 (8)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Musculoskeletal and connective-tissue disorders<a href="#t3fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">32 (12)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">28 (12)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Infections and infestations<a href="#t3fn8" role="doc-noteref">††</a></td><td class="xbxx-borders">30 (12)</td><td class="xbxx-borders">6 (2)</td><td class="xbxx-borders">1 (&lt;1)</td><td class="xbxx-borders">22 (10)</td><td class="xbxx-borders">4 (2)</td><td class="xbxr-borders">3 (1)</td></tr></tbody></table></div><figcaption><div class="caption">Summary of Treatment-Related Adverse Events in the Safety Population.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Shown are adverse events of any grade that occurred in at least 10% of the patients in either treatment group and adverse events of grade 3 or higher that occurred in at least 5% of the patients in either treatment group. The safety population included all the patients who received at least one dose of trial treatment, irrespective of status with respect to brain metastases at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">The neutropenia category included neutropenia and decreased neutrophil count.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">The anemia category included anemia, decreased hemoglobin level, and decreased red-cell count.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">The leukopenia category included leukopenia and decreased white-cell count.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t3fn5" role="paragraph">The thrombocytopenia category included thrombocytopenia and decreased platelet count.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t3fn6" role="paragraph">With respect to skin and subcutaneous disorders, there was one grade 3 rash in each of the sacituzumab govitecan and chemotherapy groups.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t3fn7" role="paragraph">There were no grade 3 or 4 neuropathy events with sacituzumab govitecan. In the chemotherapy group, there were grade 3 events of peripheral neuropathy (in two patients) and peripheral sensory neuropathy (in two patients).</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t3fn8" role="paragraph">For this category, the overall incidence of adverse events of any grade was at least 10%, but the incidence of all individual adverse events of any grade was 5% or less.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="t3fn9" role="paragraph">There was one case of grade 3 pneumonitis in the sacituzumab govitecan group (see the <a href="#ap2">Supplementary Appendix</a>); there were none in the chemotherapy group.</div></div></div></figcaption></figure></div><div role="paragraph">Neutropenia was managed with dose reduction, dose delay, or both and with growth-factor support after day 1 of cycle 1. The incidence of grade 3 and 4 febrile neutropenia was 5% and 1%, respectively, with sacituzumab govitecan and 2% and less than 1%, respectively, with chemotherapy. Concomitant growth-factor support was given to 49% of the patients treated with sacituzumab govitecan and 23% of those treated with chemotherapy. (For dose-modification recommendations for severe neutropenia and nonneutropenic toxic effects, see Fig. S8.) Diarrhea (predominantly of grade 1) was a common adverse event; the incidence of grade 3 diarrhea was 10% with sacituzumab govitecan and less than 1% with chemotherapy, and no grade 4 events were noted in either group (<a href="#t3">Table 3</a>).</div><div role="paragraph">Serious treatment-related adverse events were reported in 39 patients (15%) treated with sacituzumab govitecan and 19 patients (8%) treated with chemotherapy. Dose reductions due to adverse events occurred with similar frequency in the two groups (22% of the patients who received sacituzumab govitecan and 26% of those who received chemotherapy). Adverse events leading to treatment discontinuation were infrequent, occurring in 12 patients (5%) in each group. A total of 3 patients treated with sacituzumab govitecan and 3 treated with chemotherapy died owing to adverse events (in the sacituzumab govitecan group, owing to respiratory failure [2 patients] and postobstructive pneumonia [1 patient]; in the chemotherapy group, owing to neutropenic sepsis, sepsis, and general physical health deterioration related to progressive disease [1 patient each]). None of the deaths in the sacituzumab govitecan group were deemed to be treatment-related, whereas one death in the chemotherapy group was deemed to be treatment-related (neutropenic sepsis; see the Results section in the <a href="#ap2">Supplementary Appendix</a>).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">This phase 3, randomized clinical trial involving patients with metastatic triple-negative breast cancer showed a significant benefit of sacituzumab govitecan, a Trop-2–directed antibody–drug conjugate, over chemotherapy with respect to progression-free survival (hazard ratio for disease progression or death, 0.41; P&lt;0.001) and overall survival (hazard ratio for death, 0.48; P&lt;0.001). The benefit with sacituzumab govitecan was seen in all clinical and prespecified subgroups, including patients who received previous treatment with PD-1 or PD-L1 inhibitors. The percentage of patients with an objective response was higher with sacituzumab govitecan than with chemotherapy (35% vs. 5%). A similar clinical benefit in progression-free and overall survival was observed in the full trial population of patients with or without brain metastases.</div><div role="paragraph">Although cross-trial comparisons should be made with caution, the results with single-agent chemotherapy (control group) that were observed in this trial are broadly consistent with survival rates in previous studies.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6 r7 r8 r9" id="body-ref-r9-2" href-manipulated="true">5-9</a></sup> The KEYNOTE-119 trial, which involved patients who were less heavily pretreated than those in the ASCENT trial, compared second- or third-line pembrolizumab with standard chemotherapy; efficacy outcomes were aligned with historical expectations of single-agent chemotherapy (median progression-free survival of 3.3 months and median overall survival of 10.8 months).<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-3" href-manipulated="true" aria-label="Reference 9">9</a></sup> A pooled analysis of two phase 3 studies (EMBRACE and Study 301) included 428 patients with triple-negative breast cancer: 243 patients received eribulin, and 185 received control (treatment of the physician’s choice in EMBRACE and capecitabine in Study 301). The pooled analysis showed a 2.8-month median progression-free survival and 12.9-month median overall survival with eribulin and a 2.6-month progression-free survival and 8.2-month overall survival with standard chemotherapy.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27" href-manipulated="true" aria-label="Reference 27">27</a></sup></div><div role="paragraph">Sacituzumab govitecan has toxic effects that may require management; however, our trial showed a low incidence of treatment discontinuation due to adverse events (5%). Sacituzumab govitecan was administered over a long duration, up to 22.9 months (median, 4.4 months). The most clinically relevant grade 3 or 4 adverse events with sacituzumab govitecan were neutropenia and diarrhea, which were managed with established supportive care measures. The incidence of treatment-related pneumonitis or interstitial lung disease was low, with only one patient having reversible grade 3 pneumonitis in the context of multiple confounding factors.</div><div role="paragraph">Although sacituzumab govitecan is the only antibody–drug conjugate approved for metastatic triple-negative breast cancer in the United States, antibody–drug conjugates have been established as treatment options in HER2-positive breast cancer.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup> Both ado-trastuzumab emtansine (T-DM1)<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29-1" href-manipulated="true" aria-label="Reference 29">29</a></sup> and fam-trastuzumab deruxtecan-nxki (DS-8201a)<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30" id="body-ref-r30" href-manipulated="true" aria-label="Reference 30">30</a></sup> are approved for patients with HER2-positive disease. Ado-trastuzumab emtansine combines trastuzumab with a microtubule inhibitor DM1 through a thioether linker, with toxic effects (e.g., thrombocytopenia and hepatotoxic effects) associated with the cytotoxic component.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29-2" href-manipulated="true" aria-label="Reference 29">29</a></sup> Fam-trastuzumab deruxtecan-nxki combines an anti-HER2 fam-trastuzumab with a topoisomerase inhibitor, deruxtecan (an exatecan derivative), as its payload, with toxic effects (myelosuppression, diarrhea, and the rare but known toxic effect of potentially fatal interstitial lung disease) associated with the cytotoxic component.<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31" id="body-ref-r31" href-manipulated="true" aria-label="Reference 31">31</a></sup></div><div role="paragraph">Potential limitations of the current trial included the number of patients assigned to the chemotherapy group (32) who withdrew consent before the initiation of trial treatment or who decided not to start trial treatment. The comparison of sacituzumab govitecan with multiple standard-of-care chemotherapies also provided some challenges owing to the heterogeneity of safety risks associated with each chemotherapy agent, and the trial was not powered to examine differences between the individual agents. Tissue biopsies were optional rather than protocol-mandated immediately before trial entry.</div><div role="paragraph">Sacituzumab govitecan is a first-in-class, Trop-2–directed antibody–drug conjugate<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-3" href-manipulated="true" aria-label="Reference 18">18</a></sup>; it showed a significant benefit with respect to progression-free and overall survival as compared with standard-of-care chemotherapy. Toxic effects, particularly myelosuppression and diarrhea, were more frequent with sacituzumab govitecan than with chemotherapy. Multiple studies of sacituzumab govitecan involving patients with breast cancer are under way, including evaluation of the agent as neoadjuvant therapy in early triple-negative breast cancer (NeoSTAR [ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT04230109" target="_blank">NCT04230109</a>]), as adjuvant therapy (GBG102-SASCIA [EudraCT number, <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004100-35" target="_blank">2019-004100-35</a>]), in the metastatic context in combination with immunotherapy-based regimens (Morpheus-TNBC [ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03424005" target="_blank">NCT03424005</a>] and Saci-IO TNBC [<a href="http://clinicaltrials.gov/show/NCT04468061" target="_blank">NCT04468061</a>]) or with a PARP inhibitor (<a href="http://clinicaltrials.gov/show/NCT04039230" target="_blank">NCT04039230</a>) in advanced triple-negative breast cancer, and in hormone receptor–positive and HER2-negative metastatic breast cancer (TROPiCS-02 [<a href="http://clinicaltrials.gov/show/NCT03901339" target="_blank">NCT03901339</a>]).</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by Immunomedics, a subsidiary of Gilead Sciences.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients and their caregivers for helping us realize the possibilities of this research; the dedicated clinical trial investigators and their devoted team members who participated in this trial; William A. Wegener, M.D., Ph.D., and Robert M. Sharkey, Ph.D., for their work in the initiation of the ASCENT trial; John Benedetto, M.S., and Leonor Nazareno, B.A., who performed the trial management; Qifa Han, Ph.D., for biostatistical analysis and programming support; Sharon K. Wyhopen, Ph.D., for critical review of an earlier version of the manuscript and participation in discussions; the members of the data and safety monitoring committee (Julie R. Gralow, M.D., Vered Stearns, M.D., and Wasima Rida, Ph.D.); and Julie Kern, Ph.D., C.M.P.P., and Shala Thomas, Ph.D., C.M.P.P., at Team 9 Science for medical writing and editorial assistance with an earlier version of the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2028485_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2028485/suppl_file/nejmoa2028485_protocol.pdf" download="nejmoa2028485_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2028485_protocol.pdf" data-doi="10.1056/NEJMoa2028485">Download</a></li><li>1.88 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2028485_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2028485/suppl_file/nejmoa2028485_appendix.pdf" download="nejmoa2028485_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2028485_appendix.pdf" data-doi="10.1056/NEJMoa2028485">Download</a></li><li>1.55 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2028485_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2028485/suppl_file/nejmoa2028485_disclosures.pdf" download="nejmoa2028485_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2028485_disclosures.pdf" data-doi="10.1056/NEJMoa2028485">Download</a></li><li>1.57 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2028485_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2028485/suppl_file/nejmoa2028485_data-sharing.pdf" download="nejmoa2028485_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2028485_data-sharing.pdf" data-doi="10.1056/NEJMoa2028485">Download</a></li><li>68.22 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Anders CK, Zagar TM, Carey LA. The management of early-stage and metastatic triple-negative breast cancer: a review. <em>Hematol Oncol Clin North Am</em> 2013;27:737-749.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.hoc.2013.05.003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23915742/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000323798000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+management+of+early-stage+and+metastatic+triple-negative+breast+cancer%3A+a+review.&amp;publication_year=2013&amp;journal=Hematol+Oncol+Clin+North+Am&amp;pages=737-749&amp;doi=10.1016%2Fj.hoc.2013.05.003&amp;pmid=23915742" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. <em>Breast Cancer (Auckl)</em> 2016;10:25-36.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27042088/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375123300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+review+of+systemic+treatment+in+metastatic+triple-negative+breast+cancer.&amp;publication_year=2016&amp;journal=Breast+Cancer+%28Auckl%29&amp;pages=25-36&amp;pmid=27042088" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] 2 [HER2]) have poor survival outcomes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] metastatic triple-negative breast cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). <em>Breast</em> 2017;31:244-259.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.breast.2016.10.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27927580/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000390586600039" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=3rd+ESO-ESMO+international+consensus+guidelines+for+Advanced+Breast+Cancer+%28ABC+3%29.&amp;publication_year=2017&amp;journal=Breast&amp;pages=244-259&amp;doi=10.1016%2Fj.breast.2016.10.001&amp;pmid=27927580" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer version 5.2020. July 15, 2020.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=NCCN+clinical+practice+guidelines+in+oncology%3A+breast+cancer+version+5.2020&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. <em>Breast Cancer Res Treat</em> 2010;121:261-271.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10549-010-0824-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20229176/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000277906500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+ixabepilone+in+ER%2FPR%2FHER2-negative+%28triple-negative%29+breast+cancer.&amp;publication_year=2010&amp;journal=Breast+Cancer+Res+Treat&amp;pages=261-271&amp;doi=10.1007%2Fs10549-010-0824-0&amp;pmid=20229176" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rates and short progression-free survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with survival rates in previous studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. <em>Breast Cancer Res Treat</em> 2012;133:1067-1075.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10549-012-2008-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22415477/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000305914900024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Second-line+bevacizumab-containing+therapy+in+patients+with+triple-negative+breast+cancer%3A+subgroup+analysis+of+the+RIBBON-2+trial.&amp;publication_year=2012&amp;journal=Breast+Cancer+Res+Treat&amp;pages=1067-1075&amp;doi=10.1007%2Fs10549-012-2008-6&amp;pmid=22415477" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rates and short progression-free survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with survival rates in previous studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Pivot X, Marmé F, Koenigsberg R, Guo M, Berrak E, Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. <em>Ann Oncol</em> 2016;27:1525-1531.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdw203" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27177860/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000383182800021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pooled+analyses+of+eribulin+in+metastatic+breast+cancer+patients+with+at+least+one+prior+chemotherapy.&amp;publication_year=2016&amp;journal=Ann+Oncol&amp;pages=1525-1531&amp;doi=10.1093%2Fannonc%2Fmdw203&amp;pmid=27177860" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rates and short progression-free survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with survival rates in previous studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Park IH, Im S-A, Jung KH, et al. Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: PROCEED trial (KCSG BR 11-01). <em>Cancer Res Treat</em> 2019;51:43-52.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4143/crt.2017.562" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29458237/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455439600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+open+label+phase+III+trial+of+irinotecan+plus+capecitabine+versus+capecitabine+monotherapy+in+patients+with+metastatic+breast+cancer+previously+treated+with+anthracycline+and+taxane%3A+PROCEED+trial+%28KCSG+BR+11-01%29.&amp;publication_year=2019&amp;journal=Cancer+Res+Treat&amp;pages=43-52&amp;doi=10.4143%2Fcrt.2017.562&amp;pmid=29458237" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rates and short progression-free survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with survival rates in previous studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Cortés J, Lipatov ON, Im S-A, et al. KEYNOTE-119: phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). <em>Ann Oncol</em> 2019;30:Suppl 5:v859-v860 (<a href="https://www.annalsofoncology.org/article/S0923-7534(19)60370-4/pdf">https://www.annalsofoncology.org/article/S0923-7534(19)60370-4/pdf</a>). abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=KEYNOTE-119%3A+phase+III+study+of+pembrolizumab+%28pembro%29+versus+single-agent+chemotherapy+%28chemo%29+for+metastatic+triple+negative+breast+cancer+%28mTNBC%29.&amp;publication_year=2019&amp;pages=v859-v860" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rates and short progression-free survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with survival rates in previous studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] median overall survival of 10.8 months). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). <em>Clin Cancer Res</em> 2001;7:2182-2194.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11489791/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000170328300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+pharmacokinetics+and+metabolism+of+irinotecan+%28CPT-11%29.&amp;publication_year=2001&amp;journal=Clin+Cancer+Res&amp;pages=2182-2194&amp;pmid=11489791" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Moon S-J, Govindan SV, Cardillo TM, D’Souza CA, Hansen HJ, Goldenberg DM. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. <em>J Med Chem</em> 2008;51:6916-6926.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1021/jm800719t" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18939816/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000260730900031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antibody+conjugates+of+7-ethyl-10-hydroxycamptothecin+%28SN-38%29+for+targeted+cancer+chemotherapy.&amp;publication_year=2008&amp;journal=J+Med+Chem&amp;pages=6916-6926&amp;doi=10.1021%2Fjm800719t&amp;pmid=18939816" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). <em>Oncotarget</em> 2015;6:22496-22512.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.18632/oncotarget.4318" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26101915/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Trop-2+is+a+novel+target+for+solid+cancer+therapy+with+sacituzumab+govitecan+%28IMMU-132%29%2C+an+antibody-drug+conjugate+%28ADC%29.&amp;publication_year=2015&amp;journal=Oncotarget&amp;pages=22496-22512&amp;doi=10.18632%2Foncotarget.4318&amp;pmid=26101915" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] through a proprietary hydrolyzable linker. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] targeted delivery of SN-38 to tumor cells. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] SN-38 release after internalization. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Ripani E, Sacchetti A, Corda D, Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. <em>Int J Cancer</em> 1998;76:671-676.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/(SICI)1097-0215(19980529)76:5%3C671::AID-IJC10%3E3.0.CO;2-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9610724/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000073774500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+Trop-2+is+a+tumor-associated+calcium+signal+transducer.&amp;publication_year=1998&amp;journal=Int+J+Cancer&amp;pages=671-676&amp;doi=10.1002%2F%28SICI%291097-0215%2819980529%2976%3A5%253C671%3A%3AAID-IJC10%253E3.0.CO%3B2-7&amp;pmid=9610724" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. <em>Onco Targets Ther</em> 2019;12:1781-1790.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/OTT.S162447" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30881031/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460074000003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+Trop-2+in+solid+tumors%3A+future+prospects.&amp;publication_year=2019&amp;journal=Onco+Targets+Ther&amp;pages=1781-1790&amp;doi=10.2147%2FOTT.S162447&amp;pmid=30881031" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] types, including breast cancer (&gt;90%). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] SN-38 release after internalization. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Basu A, Goldenberg DM, Stein R. The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. <em>Int J Cancer</em> 1995;62:472-479.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ijc.2910620419" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7635574/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1995RP81600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+epithelial%2Fcarcinoma+antigen+EGP-1%2C+recognized+by+monoclonal+antibody+RS7-3G11%2C+is+phosphorylated+on+serine+303.&amp;publication_year=1995&amp;journal=Int+J+Cancer&amp;pages=472-479&amp;doi=10.1002%2Fijc.2910620419&amp;pmid=7635574" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. <em>Clin Cancer Res</em> 2011;17:3157-3169.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-10-2939" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21372224/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000290610000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Humanized+anti-Trop-2+IgG-SN-38+conjugate+for+effective+treatment+of+diverse+epithelial+cancers%3A+preclinical+studies+in+human+cancer+xenograft+models+and+monkeys.&amp;publication_year=2011&amp;journal=Clin+Cancer+Res&amp;pages=3157-3169&amp;doi=10.1158%2F1078-0432.CCR-10-2939&amp;pmid=21372224" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). <em>Clin Cancer Res</em> 2015;21:5131-5138.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-15-0670" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26106073/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000364488700021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Enhanced+delivery+of+SN-38+to+human+tumor+xenografts+with+an+anti-Trop-2-SN-38+antibody+conjugate+%28sacituzumab+govitecan%29.&amp;publication_year=2015&amp;journal=Clin+Cancer+Res&amp;pages=5131-5138&amp;doi=10.1158%2F1078-0432.CCR-15-0670&amp;pmid=26106073" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. <em>J Hematol Oncol</em> 2021;14:20-20.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13045-021-01035-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33509252/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000613226600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antibody-drug+conjugates+in+solid+tumors%3A+a+look+into+novel+targets.&amp;publication_year=2021&amp;journal=J+Hematol+Oncol&amp;pages=20-20&amp;doi=10.1186%2Fs13045-021-01035-z&amp;pmid=33509252" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] SN-38 release after internalization. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] toxic effects with sacituzumab govitecan. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Trop-2–directed antibody–drug conjugate </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. <em>MAbs</em> 2019;11:987-995.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/19420862.2019.1632115" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31208270/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000478126200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antibody-drug+conjugates+targeting+TROP-2+and+incorporating+SN-38%3A+a+case+study+of+anti-TROP-2+sacituzumab+govitecan.&amp;publication_year=2019&amp;journal=MAbs&amp;pages=987-995&amp;doi=10.1080%2F19420862.2019.1632115&amp;pmid=31208270" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. <em>Bioconjug Chem</em> 2015;26:919-931.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1021/acs.bioconjchem.5b00223" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25915780/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000355053900015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sacituzumab+govitecan+%28IMMU-132%29%2C+an+anti-Trop-2%2FSN-38+antibody-drug+conjugate%3A+characterization+and+efficacy+in+pancreatic%2C+gastric%2C+and+other+cancers.&amp;publication_year=2015&amp;journal=Bioconjug+Chem&amp;pages=919-931&amp;doi=10.1021%2Facs.bioconjchem.5b00223&amp;pmid=25915780" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase 1/2 IMMU-132-01 basket trial. <em>Annal Oncol</em> 2021 March 16 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2021.03.005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33741442/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000648935000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sacituzumab+govitecan%2C+a+Trop-2%E2%80%93directed+antibody-drug+conjugate%2C+for+patients+with+epithelial+cancer%3A+final+safety+and+efficacy+results+from+the+phase+1%2F2+IMMU-132-01+basket+trial.&amp;publication_year=2021&amp;journal=Annal+Oncol&amp;doi=10.1016%2Fj.annonc.2021.03.005&amp;pmid=33741442" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. <em>J Clin Oncol</em> 2017;35:2141-2148.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.70.8297" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28291390/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404378800009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+anti-Trop-2+antibody+drug+conjugate+sacituzumab+govitecan+%28IMMU-132%29+in+heavily+pretreated+patients+with+metastatic+triple-negative+breast+cancer.&amp;publication_year=2017&amp;journal=J+Clin+Oncol&amp;pages=2141-2148&amp;doi=10.1200%2FJCO.2016.70.8297&amp;pmid=28291390" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. <em>N Engl J Med</em> 2019;380:741-751.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_24_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2028485&amp;key=10.1056%2FNEJMoa1814213&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30786188/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000459149500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sacituzumab+govitecan-hziy+in+refractory+metastatic+triple-negative+breast+cancer.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=741-751&amp;doi=10.1056%2FNEJMoa1814213&amp;pmid=30786188" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in metastatic, epithelial cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] was observed with sacituzumab govitecan. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] toxic effects with sacituzumab govitecan. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer. April 22, 2020 (<a href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sacituzumab-govitecan-hziy-metastatic-triple-negative-breast-cancer">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sacituzumab-govitecan-hziy-metastatic-triple-negative-breast-cancer</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=FDA+grants+accelerated+approval+to+sacituzumab+govitecan-hziy+for+metastatic+triple+negative+breast+cancer&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. <em>J Clin Oncol</em> 2010;28:2784-2795.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2009.25.6529" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20404251/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000278108800020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=American+Society+of+Clinical+Oncology%2FCollege+of+American+Pathologists+guideline+recommendations+for+immunohistochemical+testing+of+estrogen+and+progesterone+receptors+in+breast+cancer.&amp;publication_year=2010&amp;journal=J+Clin+Oncol&amp;pages=2784-2795&amp;doi=10.1200%2FJCO.2009.25.6529&amp;pmid=20404251" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). <em>Eur J Cancer</em> 2009;45:228-247.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ejca.2008.10.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19097774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000262948300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+response+evaluation+criteria+in+solid+tumours%3A+revised+RECIST+guideline+%28version+1.1%29.&amp;publication_year=2009&amp;journal=Eur+J+Cancer&amp;pages=228-247&amp;doi=10.1016%2Fj.ejca.2008.10.026&amp;pmid=19097774" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Twelves C, Cortes J, Vahdat L, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. <em>Breast Cancer Res Treat</em> 2014;148:553-561.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10549-014-3144-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25381136/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345370600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+eribulin+in+women+with+metastatic+breast+cancer%3A+a+pooled+analysis+of+two+phase+3+studies.&amp;publication_year=2014&amp;journal=Breast+Cancer+Res+Treat&amp;pages=553-561&amp;doi=10.1007%2Fs10549-014-3144-y&amp;pmid=25381136" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. <em>Ther Adv Med Oncol</em> 2020;12:1758835920915980-1758835920915980.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1758835920915980" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32426047/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000535757700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Novel+antibody-drug+conjugates+for+triple+negative+breast+cancer.&amp;publication_year=2020&amp;journal=Ther+Adv+Med+Oncol&amp;pages=1758835920915980-1758835920915980&amp;doi=10.1177%2F1758835920915980&amp;pmid=32426047" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Kadcyla (ado-trastuzumab emtansine). South San Francisco, CA: Genentech, 2019 (prescribing information).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r29" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Kadcyla+%28ado-trastuzumab+emtansine%29.+South+San+Francisco%2C+CA%3A+Genentech%2C+2019+%28prescribing+information%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r29" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r29-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Both ado-trastuzumab emtansine (T-DM1) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] associated with the cytotoxic component. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Enhertu (fam-trastuzumab deruxtecan-nxki). Basking Ridge, NJ: Daiichi Sankyo, December 2019 (prescribing information).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Enhertu+%28fam-trastuzumab+deruxtecan-nxki%29.+Basking+Ridge%2C+NJ%3A+Daiichi+Sankyo%2C+December+2019+%28prescribing+information%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. <em>Clin Cancer Res</em> 2016;22:5097-5108.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-15-2822" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27026201/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385632700018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DS-8201a%2C+a+novel+HER2-targeting+ADC+with+a+novel+DNA+topoisomerase+I+inhibitor%2C+demonstrates+a+promising+antitumor+efficacy+with+differentiation+from+T-DM1.&amp;publication_year=2016&amp;journal=Clin+Cancer+Res&amp;pages=5097-5108&amp;doi=10.1158%2F1078-0432.CCR-15-2822&amp;pmid=27026201" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/384/16"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">384</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">16</span></span> • <span property="datePublished">April 22, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1529</span>-<span property="pageEnd">1541</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2028485" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2028485?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: April 21, 2021</div><div><b class="core-label">Published in issue</b>: April 22, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/breast-cancer" alt="View article keyword Breast Cancer" data-interactiontype="article_recirculation_click">Breast Cancer</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Aditya</span> <span property="familyName">Bardia</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sara A.</span> <span property="familyName">Hurvitz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sara M.</span> <span property="familyName">Tolaney</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Delphine</span> <span property="familyName">Loirat</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kevin</span> <span property="familyName">Punie</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mafalda</span> <span property="familyName">Oliveira</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Adam</span> <span property="familyName">Brufsky</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sagar D.</span> <span property="familyName">Sardesai</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kevin</span> <span property="familyName">Kalinsky</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Amelia B.</span> <span property="familyName">Zelnak</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert</span> <span property="familyName">Weaver</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tiffany</span> <span property="familyName">Traina</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Florence</span> <span property="familyName">Dalenc</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Philippe</span> <span property="familyName">Aftimos</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Filipa</span> <span property="familyName">Lynce</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sami</span> <span property="familyName">Diab</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Javier</span> <span property="familyName">Cortés</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Joyce</span> <span property="familyName">O’Shaughnessy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Véronique</span> <span property="familyName">Diéras</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Cristiano</span> <span property="familyName">Ferrario</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter</span> <span property="familyName">Schmid</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lisa A.</span> <span property="familyName">Carey</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Luca</span> <span property="familyName">Gianni</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Martine J.</span> <span property="familyName">Piccart</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sibylle</span> <span property="familyName">Loibl</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David M.</span> <span property="familyName">Goldenberg</span>, <span property="honorificSuffix">Sc.D., M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Quan</span> <span property="familyName">Hong</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Martin S.</span> <span property="familyName">Olivo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Loretta M.</span> <span property="familyName">Itri</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Hope S.</span> <span property="familyName">Rugo</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the ASCENT Clinical Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Division of Medical Oncology, Massachusetts General Hospital Cancer Center (A. Bardia), and the Department of Medical Oncology, Dana–Farber Cancer Institute (S.M.T.) — both in Boston; the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); the Medical Oncology Department and the Department of Drug Development and Innovation, Institut Curie, Paris (D.L.), Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (F.D.), and the Department of Medical Oncology, Centre Eugène Marquis, Rennes (V.D.) — all in France; the Department of General Medical Oncology and Multidisciplinary Breast Center, Leuven Cancer Institute, University Hospitals Leuven, Leuven (K.P.), and the Clinical Trials Conduct Unit (P.A.), Institut Jules Bordet–Université Libre de Bruxelles (M.J.P.), Brussels — all in Belgium; the Medical Oncology Department and Breast Cancer Group, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (M.O.), and the International Breast Cancer Center, Quiron Group (J.C.) — all in Barcelona; Magee–Womens Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh (A. Brufsky); Ohio State University Wexner Medical Center, Columbus (S.D.S.); Columbia University Irving Medical Center (K.K.) and Memorial Sloan Kettering Cancer Center (T.T.) — both in New York; Northside Hospital, Atlanta (A.B.Z.); Florida Cancer Specialists, Tampa (R.W.); Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (F.L.); Rocky Mountain Cancer Centers, Greenwood Village, CO (S.D.); Baylor University Medical Center and Texas Oncology, Dallas (J.O.); Segal Cancer Centre, Jewish General Hospital, Montreal (C.F.); Barts Cancer Institute, Queen Mary University of London, London (P.S.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (L.A.C.); Gianni Bonadonna Foundation, Milan (L.G.); the Department of Medicine and Research, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany (S.L.); Immunomedics, Morris Plains, NJ (D.M.G., Q.H., M.S.O., L.M.I.); and the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Bardia at the Massachusetts General Hospital Cancer Center, BHX 237, 55 Fruit St., Boston, MA 02114, or at <a href="mailto:bardia.aditya@mgh.harvard.edu">bardia.aditya@mgh.harvard.edu</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the ASCENT Clinical Trial Investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">939</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2028485" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="d28ce8dc-e771-7dc1-3e1b-fbde77ce579b"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104446117" style="display:inline-block;">
                <img alt="Article has an altmetric score of 528" src="https://badges.altmetric.com/?size=320&amp;score=528&amp;types=mabcttfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104446117">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_d28ce8dc-e771-7dc1-3e1b-fbde77ce579b" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104446117&amp;tab=news">
          Picked up by <b>53</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104446117&amp;tab=blogs">
          Blogged by <b>6</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104446117&amp;tab=policy-documents">
          Referenced in <b>3</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104446117&amp;tab=twitter">
          Posted by <b>179</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104446117&amp;tab=patents">
          Referenced in <b>3</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104446117&amp;tab=facebook">
          On <b>5</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104446117&amp;tab=guidelines">
          Referenced in <b>4</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>971</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d67ae42361628a-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2028485"> <input type="hidden" name="downloadFileName" value="csp_384_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2028485%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-16%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="939" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Federica Miglietta, </li><li class="list-inline-item cited-by__entry__author">Mario Pirozzi, </li><li class="list-inline-item cited-by__entry__author">Michele Bottosso, </li><li class="list-inline-item cited-by__entry__author">Carla Pisani, </li><li class="list-inline-item cited-by__entry__author">Pierfrancesco Franco, </li><li class="list-inline-item cited-by__entry__author">Valentina Guarnieri, </li><li class="list-inline-item cited-by__entry__author">Alessandra Gennari, </li></ul><span class="cited-by__entry__title">Anaemia in cancer patients: Advances and challenges in the era of precision oncology, </span><span class="cited-by__entry__series-title">Critical Reviews in Oncology/Hematology, </span><span class="cited-by__entry__volume"><strong>213</strong>, </span><span class="cited-by__entry__page-range">(104788), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.critrevonc.2025.104788" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.critrevonc.2025.104788</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.critrevonc.2025.104788" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mokhtar Rejili, </li></ul><span class="cited-by__entry__title">Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy, </span><span class="cited-by__entry__series-title">Pathology - Research and Practice, </span><span class="cited-by__entry__volume"><strong>272</strong>, </span><span class="cited-by__entry__page-range">(156075), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.prp.2025.156075" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.prp.2025.156075</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.prp.2025.156075" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">L. Posado-Domínguez, </li></ul><span class="cited-by__entry__title">Cancer: Fight Club?, </span><span class="cited-by__entry__series-title">Medicina de Familia. SEMERGEN, </span><span class="cited-by__entry__volume"><strong>51</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(102415), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.semerg.2024.102415" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.semerg.2024.102415</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.semerg.2024.102415" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zhiyuan Yao, </li><li class="list-inline-item cited-by__entry__author">Ge Wei, </li><li class="list-inline-item cited-by__entry__author">Peng Song, </li><li class="list-inline-item cited-by__entry__author">Changlei Li, </li><li class="list-inline-item cited-by__entry__author">Guohua Wang, </li><li class="list-inline-item cited-by__entry__author">Zengjin Wen, </li><li class="list-inline-item cited-by__entry__author">Lisai Liu, </li><li class="list-inline-item cited-by__entry__author">Guangqi Li, </li></ul><span class="cited-by__entry__title">Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: Implications for combined immunotherapy and ADC targeted therapies, </span><span class="cited-by__entry__series-title">Pathology - Research and Practice, </span><span class="cited-by__entry__volume"><strong>271</strong>, </span><span class="cited-by__entry__page-range">(156032), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.prp.2025.156032" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.prp.2025.156032</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.prp.2025.156032" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Luísa Soares Miranda, </li><li class="list-inline-item cited-by__entry__author">Maria João Sousa, </li><li class="list-inline-item cited-by__entry__author">Miguel Martins Braga, </li><li class="list-inline-item cited-by__entry__author">Marisa Couto, </li><li class="list-inline-item cited-by__entry__author">Isabel Vieira Fernandes, </li><li class="list-inline-item cited-by__entry__author">Francisca Abreu, </li><li class="list-inline-item cited-by__entry__author">Inês Eiriz, </li><li class="list-inline-item cited-by__entry__author">Catarina Lopes Fernandes, </li><li class="list-inline-item cited-by__entry__author">Alice Fonseca Marques, </li><li class="list-inline-item cited-by__entry__author">Maria Teresa Marques, </li><li class="list-inline-item cited-by__entry__author">Raquel Romão, </li><li class="list-inline-item cited-by__entry__author">Fernando Gonçalves, </li><li class="list-inline-item cited-by__entry__author">Joana Simões, </li><li class="list-inline-item cited-by__entry__author">António Araújo, </li></ul><span class="cited-by__entry__title">Trastuzumab Deruxtecan in Previously Treated HER2-Low Metastatic Breast Cancer: Real-World Multicentric Study in the Portuguese Population, </span><span class="cited-by__entry__series-title">Cancers, </span><span class="cited-by__entry__volume"><strong>17</strong>, </span><span class="cited-by__entry__issue">12, </span><span class="cited-by__entry__page-range">(1911), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/cancers17121911" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/cancers17121911</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/cancers17121911" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dionisia Quiroga, </li><li class="list-inline-item cited-by__entry__author">Charles Pei, </li><li class="list-inline-item cited-by__entry__author">Julie A. Stephens, </li><li class="list-inline-item cited-by__entry__author">Kai C. C. Johnson, </li><li class="list-inline-item cited-by__entry__author">Nicole Williams, </li><li class="list-inline-item cited-by__entry__author">Preeti Sudheendra, </li><li class="list-inline-item cited-by__entry__author">Mathew Cherian, </li><li class="list-inline-item cited-by__entry__author">Daniel Stover, </li><li class="list-inline-item cited-by__entry__author">Ashley Davenport, </li><li class="list-inline-item cited-by__entry__author">Margaret Gatti-Mays, </li><li class="list-inline-item cited-by__entry__author">Robert Wesolowski, </li><li class="list-inline-item cited-by__entry__author">Jose G. Bazan, </li><li class="list-inline-item cited-by__entry__author">Sasha Beyer, </li><li class="list-inline-item cited-by__entry__author">Ko Un Park, </li><li class="list-inline-item cited-by__entry__author">Bridget A. Oppong, </li><li class="list-inline-item cited-by__entry__author">Julia White, </li><li class="list-inline-item cited-by__entry__author">Sachin R. Jhawar, </li><li class="list-inline-item cited-by__entry__author">Sagar Sardesai, </li></ul><span class="cited-by__entry__title">Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in non-metastatic HER2-negative breast cancer: a US National Cancer Database analysis, </span><span class="cited-by__entry__series-title">Therapeutic Advances in Medical Oncology, </span><span class="cited-by__entry__volume"><strong>17</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1177/17588359251342874" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1177/17588359251342874</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1177/17588359251342874" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Tatiana V Denisenko, </li><li class="list-inline-item cited-by__entry__author">Anna E Ivanova, </li><li class="list-inline-item cited-by__entry__author">Alexey Koval, </li><li class="list-inline-item cited-by__entry__author">Denis N Silachev, </li><li class="list-inline-item cited-by__entry__author">Lee Jia, </li><li class="list-inline-item cited-by__entry__author">Gennadiy T Sukhikh, </li><li class="list-inline-item cited-by__entry__author">Vladimir L Katanaev, </li></ul><span class="cited-by__entry__title">Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers, </span><span class="cited-by__entry__series-title">Molecular Systems Biology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s44320-025-00125-1" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s44320-025-00125-1</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s44320-025-00125-1" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Quchang Ouyang, </li><li class="list-inline-item cited-by__entry__author">Jordi Rodon, </li><li class="list-inline-item cited-by__entry__author">Yan Liang, </li><li class="list-inline-item cited-by__entry__author">Xinhong Wu, </li><li class="list-inline-item cited-by__entry__author">Qun Li, </li><li class="list-inline-item cited-by__entry__author">Lihua Song, </li><li class="list-inline-item cited-by__entry__author">Min Yan, </li><li class="list-inline-item cited-by__entry__author">Zhongsheng Tong, </li><li class="list-inline-item cited-by__entry__author">YunPeng Liu, </li><li class="list-inline-item cited-by__entry__author">Zev A. Wainberg, </li><li class="list-inline-item cited-by__entry__author">Ying Wang, </li><li class="list-inline-item cited-by__entry__author">Cuizhi Geng, </li><li class="list-inline-item cited-by__entry__author">Susanna V. Ulahannan, </li><li class="list-inline-item cited-by__entry__author">Guohua Yu, </li><li class="list-inline-item cited-by__entry__author">Manish R. Sharma, </li><li class="list-inline-item cited-by__entry__author">Xiang Wang, </li><li class="list-inline-item cited-by__entry__author">Judy S. Wang, </li><li class="list-inline-item cited-by__entry__author">Alexander Spira, </li><li class="list-inline-item cited-by__entry__author">Weihong Zhao, </li><li class="list-inline-item cited-by__entry__author">Rachel E. Sanborn, </li><li class="list-inline-item cited-by__entry__author">Ying Cheng, </li><li class="list-inline-item cited-by__entry__author">Xian Wang, </li><li class="list-inline-item cited-by__entry__author">Gesha Liu, </li><li class="list-inline-item cited-by__entry__author">Yaling Li, </li><li class="list-inline-item cited-by__entry__author">Junyou Ge, </li><li class="list-inline-item cited-by__entry__author">Elliot Chartash, </li><li class="list-inline-item cited-by__entry__author">Omobolaji O. Akala, </li><li class="list-inline-item cited-by__entry__author">Yongmei Yin, </li></ul><span class="cited-by__entry__title">Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies, </span><span class="cited-by__entry__series-title">Journal of Hematology &amp; Oncology, </span><span class="cited-by__entry__volume"><strong>18</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s13045-025-01705-2" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s13045-025-01705-2</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s13045-025-01705-2" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Stephanie M. Robert, </li><li class="list-inline-item cited-by__entry__author">Allison Toth, </li><li class="list-inline-item cited-by__entry__author">Sapir Lev, </li><li class="list-inline-item cited-by__entry__author">Stephen G. Bowden, </li><li class="list-inline-item cited-by__entry__author">Yao Yu, </li><li class="list-inline-item cited-by__entry__author">Brandon S. Imber, </li><li class="list-inline-item cited-by__entry__author">Adrienne Boire, </li><li class="list-inline-item cited-by__entry__author">Joshua Z. Drago, </li><li class="list-inline-item cited-by__entry__author">Shanu Modi, </li><li class="list-inline-item cited-by__entry__author">Nelson S. Moss, </li></ul><span class="cited-by__entry__title">Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges, </span><span class="cited-by__entry__series-title">Journal of Neuro-Oncology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s11060-025-05083-0" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s11060-025-05083-0</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s11060-025-05083-0" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Hope S. Rugo, </li><li class="list-inline-item cited-by__entry__author">Binghe Xu, </li><li class="list-inline-item cited-by__entry__author">Anandaroop Dasgupta, </li><li class="list-inline-item cited-by__entry__author">Ankita Kaushik, </li><li class="list-inline-item cited-by__entry__author">Wendy Verret, </li><li class="list-inline-item cited-by__entry__author">Barinder Singh, </li></ul><span class="cited-by__entry__title">A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Previously Treated HR+/HER− mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials, </span><span class="cited-by__entry__series-title">Cancers, </span><span class="cited-by__entry__volume"><strong>17</strong>, </span><span class="cited-by__entry__issue">11, </span><span class="cited-by__entry__page-range">(1885), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/cancers17111885" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/cancers17111885</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/cancers17111885" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2028485%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-16%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028485" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2028485" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2028485.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028485_f1.jpg"><img src="/cms/10.1056/NEJMoa2028485/asset/ee77e7c3-1723-41ef-9d69-b22a916bc846/assets/images/large/nejmoa2028485_f1.jpg" height="2019" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Efficacy Results in Patients without Brain Metastases at Baseline and in the Full Population.</div><div class="notes"><div role="doc-footnote">Panels A and B show progression-free and overall survival, respectively, among patients without brain metastases. Progression-free survival was determined by blinded independent central review according to Response Evaluation Criteria in Solid Tumors, version 1.1. Panel C shows a waterfall plot of the best percent change in the sum of the diameters of target lesions in patients without brain metastases who had at least one response assessment by central review (212 patients in the sacituzumab govitecan group and 160 in the chemotherapy group). Asterisks at 0 denote patients who had no change from baseline in tumor size. Panel D shows progression-free survival among all randomly assigned patients (with or without brain metastases).</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028485_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028485_f2.jpg"><img src="/cms/10.1056/NEJMoa2028485/asset/e02a8b15-fcc3-4f89-812c-1bee96644cf7/assets/images/large/nejmoa2028485_f2.jpg" height="1808" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Subgroup Analysis of Progression-free Survival.</div><div class="notes"><div role="doc-footnote">NE denotes could not be evaluated, PD-1 programmed death 1, PD-L1 programmed death ligand 1, and TNBC triple-negative breast cancer.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028485_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2028485/asset/15e27d35-9b19-41e1-b7f7-aa267bed8b26/assets/images/large/nejmoa2028485_t1.jpg" height="3307" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Sacituzumab Govitecan <br>(N=235)</th><th class="txxr-borders">Chemotherapy<br>(N=233)<a href="#core-t1fn2" role="doc-noteref">†</a></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Sex — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Female</td><td class="xxxx-borders">233 (99)</td><td class="xxxr-borders">233 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders">54 (29–82)</td><td class="xxxr-borders">53 (27–81)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">188 (80)</td><td class="xxxr-borders">181 (78)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">28 (12)</td><td class="xxxr-borders shading">28 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">9 (4)</td><td class="xxxr-borders">9 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other or not specified</td><td class="xxxx-borders shading">10 (4)</td><td class="xxxr-borders shading">15 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">ECOG performance-status score at screening — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">0</td><td class="xxxx-borders shading">108 (46)</td><td class="xxxr-borders shading">98 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">1</td><td class="xxxx-borders">127 (54)</td><td class="xxxr-borders">135 (58)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Germline <i>BRCA1</i> or <i>BRCA2</i> mutation status — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Negative</td><td class="xxxx-borders">133 (57)</td><td class="xxxr-borders">125 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Positive<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">16 (7)</td><td class="xxxr-borders shading">18 (8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Triple-negative breast cancer at initial diagnosis — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">165 (70)</td><td class="xxxr-borders shading">157 (67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">70 (30)</td><td class="xxxr-borders">76 (33)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time from diagnosis of metastatic disease to enrollment (range) — mo<a href="#core-t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">15.8 (0–202.9)</td><td class="xxxr-borders shading">15.2 (0–140.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Major tumor locations — no. (%)<a href="#core-t1fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Lung</td><td class="xxxx-borders shading">108 (46)</td><td class="xxxr-borders shading">97 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Liver</td><td class="xxxx-borders">98 (42)</td><td class="xxxr-borders">101 (43)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Axillary lymph nodes</td><td class="xxxx-borders shading">57 (24)</td><td class="xxxr-borders shading">73 (31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Bone<a href="#core-t1fn10" role="doc-noteref">§§</a></td><td class="xxxx-borders">48 (20)</td><td class="xxxr-borders">55 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median no. of previous anticancer regimens (range) <a href="#core-t1fn11" role="doc-noteref">¶¶</a></td><td class="xxxx-borders shading">3 (1–16)</td><td class="xxxr-borders shading">3 (1–12)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Previous chemotherapy regimens — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">2 or 3</td><td class="xxxx-borders shading">166 (71)</td><td class="xxxr-borders shading">164 (70)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&gt;3</td><td class="xxxx-borders">69 (29)</td><td class="xxxr-borders">69 (30)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Previous chemotherapy drugs — no. (%)<a href="#core-t1fn12" role="doc-noteref">‖‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Taxanes</td><td class="xxxx-borders">235 (100)</td><td class="xxxr-borders">233 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Anthracyclines</td><td class="xxxx-borders shading">191 (81)</td><td class="xxxr-borders shading">193 (83)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cyclophosphamide</td><td class="xxxx-borders">192 (82)</td><td class="xxxr-borders">192 (82)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Carboplatin</td><td class="xxxx-borders shading">147 (63)</td><td class="xxxr-borders shading">160 (69)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Capecitabine</td><td class="xxxx-borders">147 (63)</td><td class="xxxr-borders">159 (68)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Previous use of PARP inhibitors — no. (%)</td><td class="xxxx-borders shading">17 (7)</td><td class="xxxr-borders shading">18 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Previous use of PD-1 or PD-L1 inhibitors — no. (%)</td><td class="xbxx-borders">67 (29)</td><td class="xbxr-borders">60 (26)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">PARP denotes poly(adenosine diphosphate–ribose) polymerase, PD-1 programmed death 1, and PD-L1 programmed death ligand 1.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">The chemotherapy group included patients randomly assigned to receive eribulin (126 patients), vinorelbine (47), capecitabine (31), and gemcitabine (29).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Race was reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating that the patient is fully active with no restrictions, 1 indicating that the patient is ambulatory and able to carry out work of a light or sedentary nature but restricted in physically strenuous activity, and higher numbers indicating increasing degrees of disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Patients who did not undergo <i>BRCA1</i> or <i>BRCA2</i> germline testing or who had inconclusive results are not included.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Among the patients with <i>BRCA1</i> or <i>BRCA2</i> mutations at baseline, 10 of 16 (62%) in the sacituzumab govitecan group and 11 of 18 (61%) in the chemotherapy group had previously received PARP inhibitors.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">Patients whose initial diagnosis was hormone receptor–positive or human epidermal growth factor receptor 2–positive breast cancer had a median time from diagnosis of metastatic disease to enrollment of 22.5 months (range, 2.1 to 202.9) in the sacituzumab govitecan group and 21.2 months (range, 1.1 to 140.1) in the chemotherapy group.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t1fn8" role="paragraph" data-to-manipulate="true">The time from diagnosis of metastatic disease is defined as number of days from the date of first diagnosis of metastasis to the date of trial entry divided by 30.4375.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="core-t1fn9" role="paragraph" data-to-manipulate="true">Tumor locations were based on independent central review of target and nontarget lesions at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="core-t1fn10" role="paragraph" data-to-manipulate="true">Patients with bone-only disease were not permitted in the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶¶</div><div id="core-t1fn11" role="paragraph" data-to-manipulate="true">Anticancer regimens refer to any previous regimens for metastatic or locally advanced disease or in the neoadjuvant context that were used to treat an eligible patient with breast cancer. Previous therapy in the adjuvant context is excluded from this count.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖‖</div><div id="core-t1fn12" role="paragraph" data-to-manipulate="true">Shown are most common chemotherapy drugs used. Taxanes include paclitaxel, nab-paclitaxel, and docetaxel. Anthracyclines include doxorubicin, daunorubicin, epirubicin, and different formulations of these agents.</div></div></div></figcaption></a><figcaption><div class="caption">Baseline Characteristics and Previous Treatment of Patients without Brain Metastases.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2028485/asset/52f54318-9af0-4b91-9fc7-1699d6ddbfcd/assets/images/large/nejmoa2028485_t2.jpg" height="1533" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="2"><span>Patients without Brain Metastases</span></th><th class="txxr-borders" colspan="2"><span>Full Population<a href="#core-t2fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Sacituzumab Govitecan <br>(N=235)</th><th class="xxxx-borders">Chemotherapy<br>(N=233)</th><th class="xxxx-borders">Sacituzumab Govitecan <br>(N=267)</th><th class="xxxr-borders">Chemotherapy<br>(N=262)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median progression-free survival (95% CI) — mo</td><td class="xxxx-borders shading">5.6 (4.3−6.3)</td><td class="xxxx-borders shading">1.7 (1.5−2.6)</td><td class="xxxx-borders shading">4.8 (4.1–5.8)</td><td class="xxxr-borders shading">1.7 (1.5–2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hazard ratio for disease progression or death (95% CI)</td><td class="xxxx-borders">0.41 (0.32−0.52)<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.43 (0.35−0.54)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median overall survival (95% CI) — mo</td><td class="xxxx-borders shading">12.1 (10.7−14.0)</td><td class="xxxx-borders shading">6.7 (5.8−7.7)</td><td class="xxxx-borders shading">11.8 (10.5–13.8)</td><td class="xxxr-borders shading">6.9 (5.9–7.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hazard ratio for death (95% CI)</td><td class="xxxx-borders">0.48 (0.38−0.59)<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.51 (0.41–0.62)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Objective response — no. of patients (%)<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">82 (35)</td><td class="xxxx-borders shading">11 (5)</td><td class="xxxx-borders shading">83 (31)</td><td class="xxxr-borders shading">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response</td><td class="xxxx-borders">10 (4)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">10 (4)</td><td class="xxxr-borders">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Partial response</td><td class="xxxx-borders shading">72 (31)</td><td class="xxxx-borders shading">9 (4)</td><td class="xxxx-borders shading">73 (27)</td><td class="xxxr-borders shading">9 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Clinical benefit — no. of patients (%)<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">105 (45)</td><td class="xxxx-borders">20 (9)</td><td class="xxxx-borders">108 (40)</td><td class="xxxr-borders">21 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Stable disease — no. of patients (%)</td><td class="xxxx-borders shading">81 (34)</td><td class="xxxx-borders shading">62 (27)</td><td class="xxxx-borders shading">96 (36)</td><td class="xxxr-borders shading">71 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stable disease for ≥6 mo</td><td class="xxxx-borders">23 (10)</td><td class="xxxx-borders">9 (4)</td><td class="xxxx-borders">25 (9)</td><td class="xxxr-borders">10 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Progressive disease — no. of patients (%)</td><td class="xxxx-borders shading">54 (23)</td><td class="xxxx-borders shading">89 (38)</td><td class="xxxx-borders shading">65 (24)</td><td class="xxxr-borders shading">100 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Response could not be evaluated — no. of patients (%)<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">18 (8)</td><td class="xxxx-borders">71 (30)</td><td class="xxxx-borders">23 (9)</td><td class="xxxr-borders">80 (31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time to response (95% CI) — mo</td><td class="xxxx-borders shading">1.5 (0.7−10.6)</td><td class="xxxx-borders shading">1.5 (1.3−4.2)</td><td class="xxxx-borders shading">1.5 (0.7–10.6)</td><td class="xxxr-borders shading">1.5 (1.3−4.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xxxx-borders">6.3 (5.5−9.0)</td><td class="xxxx-borders">3.6 (2.8−NE)</td><td class="xxxx-borders">6.3 (5.5–9.0)</td><td class="xxxr-borders">3.6 (2.8–NE)</td></tr><tr data-type="row"><td class="xblx-borders hanging12 shading">Hazard ratio (95% CI)</td><td class="xbxx-borders shading" data-xml-align="center">0.39 (0.14−1.07)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">NE denotes could not be estimated.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The full population includes all randomly assigned patients (with and without brain metastases).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">P&lt;0.001.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">An objective response was defined as a complete response or partial response.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">Clinical benefit was defined as a complete response, a partial response, or stable disease with a duration of at least 6 months.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t2fn6" role="paragraph" data-to-manipulate="true">Response could not be evaluated for a variety of reasons, including a lack of postbaseline images or unreadable images.</div></div></div></figcaption></a><figcaption><div class="caption">Summary of Treatment Efficacy, as Determined by Independent Central Review.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2028485/asset/6ce73d92-7733-4624-9a38-cb5c94dd9130/assets/images/large/nejmoa2028485_t3.jpg" height="2426" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="3"><span>Sacituzumab Govitecan <br>(N=258)</span></th><th class="txxr-borders" colspan="3"><span>Chemotherapy<br>(N=224)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3</th><th class="xxxx-borders">Grade 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3</th><th class="xxxr-borders">Grade 4</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="6"><span><i>number of patients (percent)</i></span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">252 (98)</td><td class="xxxx-borders shading">117 (45)</td><td class="xxxx-borders shading">48 (19)</td><td class="xxxx-borders shading">192 (86)</td><td class="xxxx-borders shading">71 (32)</td><td class="xxxr-borders shading">33 (15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Hematologic event</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Neutropenia<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">163 (63)</td><td class="xxxx-borders shading">88 (34)</td><td class="xxxx-borders shading">44 (17)</td><td class="xxxx-borders shading">96 (43)</td><td class="xxxx-borders shading">45 (20)</td><td class="xxxr-borders shading">29 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Anemia<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">89 (34)</td><td class="xxxx-borders">20 (8)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">54 (24)</td><td class="xxxx-borders">11 (5)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Leukopenia<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">41 (16)</td><td class="xxxx-borders shading">23 (9)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxx-borders shading">25 (11)</td><td class="xxxx-borders shading">10 (4)</td><td class="xxxr-borders shading">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Thrombocytopenia<a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">14 (5)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">25 (11)</td><td class="xxxx-borders">3 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Febrile neutropenia</td><td class="xxxx-borders shading">15 (6)</td><td class="xxxx-borders shading">12 (5)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxx-borders shading">5 (2)</td><td class="xxxx-borders shading">4 (2)</td><td class="xxxr-borders shading">1 (&lt;1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Gastrointestinal event</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">153 (59)</td><td class="xxxx-borders shading">27 (10)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">27 (12)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">147 (57)</td><td class="xxxx-borders">6 (2)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">59 (26)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Vomiting</td><td class="xxxx-borders shading">75 (29)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">23 (10)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Constipation</td><td class="xxxx-borders">44 (17)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">32 (14)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders shading">29 (11)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">9 (4)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">General disorders and administration-site conditions</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">115 (45)</td><td class="xxxx-borders shading">8 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">68 (30)</td><td class="xxxx-borders shading">12 (5)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asthenia</td><td class="xxxx-borders">31 (12)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">23 (10)</td><td class="xxxx-borders">3 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Skin and subcutaneous disorders: alopecia<a href="#core-t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">119 (46)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">35 (16)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Metabolism and nutrition disorders: decreased appetite</td><td class="xxxx-borders">51 (20)</td><td class="xxxx-borders">4 (2)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">32 (14)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Nervous system disorders<a href="#core-t3fn7" role="doc-noteref">**</a><a href="#core-t3fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">64 (25)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">53 (24)</td><td class="xxxx-borders shading">5 (2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Respiratory, thoracic, and mediastinal disorders<a href="#core-t3fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">41 (16)</td><td class="xxxx-borders">5 (2)<a href="#core-t3fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">17 (8)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Musculoskeletal and connective-tissue disorders<a href="#core-t3fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">32 (12)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">28 (12)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Infections and infestations<a href="#core-t3fn8" role="doc-noteref">††</a></td><td class="xbxx-borders">30 (12)</td><td class="xbxx-borders">6 (2)</td><td class="xbxx-borders">1 (&lt;1)</td><td class="xbxx-borders">22 (10)</td><td class="xbxx-borders">4 (2)</td><td class="xbxr-borders">3 (1)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t3.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t3.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Shown are adverse events of any grade that occurred in at least 10% of the patients in either treatment group and adverse events of grade 3 or higher that occurred in at least 5% of the patients in either treatment group. The safety population included all the patients who received at least one dose of trial treatment, irrespective of status with respect to brain metastases at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">The neutropenia category included neutropenia and decreased neutrophil count.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">The anemia category included anemia, decreased hemoglobin level, and decreased red-cell count.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">The leukopenia category included leukopenia and decreased white-cell count.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">The thrombocytopenia category included thrombocytopenia and decreased platelet count.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t3fn6" role="paragraph" data-to-manipulate="true">With respect to skin and subcutaneous disorders, there was one grade 3 rash in each of the sacituzumab govitecan and chemotherapy groups.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t3fn7" role="paragraph" data-to-manipulate="true">There were no grade 3 or 4 neuropathy events with sacituzumab govitecan. In the chemotherapy group, there were grade 3 events of peripheral neuropathy (in two patients) and peripheral sensory neuropathy (in two patients).</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t3fn8" role="paragraph" data-to-manipulate="true">For this category, the overall incidence of adverse events of any grade was at least 10%, but the incidence of all individual adverse events of any grade was 5% or less.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t3.jpg"><div class="label">‡‡</div></a><div id="core-t3fn9" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t3.jpg">There was one case of grade 3 pneumonitis in the sacituzumab govitecan group (see the </a><a href="#ap2">Supplementary Appendix</a>); there were none in the chemotherapy group.</div></div></div></figcaption><figcaption><div class="caption">Summary of Treatment-Related Adverse Events in the Safety Population.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028485_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2028485</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Anders CK, Zagar TM, Carey LA. The management of early-stage and metastatic triple-negative breast cancer: a review. <em>Hematol Oncol Clin North Am</em> 2013;27:737-749.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.hoc.2013.05.003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23915742/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000323798000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+management+of+early-stage+and+metastatic+triple-negative+breast+cancer%3A+a+review.&amp;publication_year=2013&amp;journal=Hematol+Oncol+Clin+North+Am&amp;pages=737-749&amp;doi=10.1016%2Fj.hoc.2013.05.003&amp;pmid=23915742" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. <em>Breast Cancer (Auckl)</em> 2016;10:25-36.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27042088/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375123300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+review+of+systemic+treatment+in+metastatic+triple-negative+breast+cancer.&amp;publication_year=2016&amp;journal=Breast+Cancer+%28Auckl%29&amp;pages=25-36&amp;pmid=27042088" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] 2 [HER2]) have poor survival outcomes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] metastatic triple-negative breast cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). <em>Breast</em> 2017;31:244-259.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.breast.2016.10.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27927580/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000390586600039" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=3rd+ESO-ESMO+international+consensus+guidelines+for+Advanced+Breast+Cancer+%28ABC+3%29.&amp;publication_year=2017&amp;journal=Breast&amp;pages=244-259&amp;doi=10.1016%2Fj.breast.2016.10.001&amp;pmid=27927580" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer version 5.2020. July 15, 2020.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=NCCN+clinical+practice+guidelines+in+oncology%3A+breast+cancer+version+5.2020&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. <em>Breast Cancer Res Treat</em> 2010;121:261-271.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10549-010-0824-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20229176/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000277906500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+ixabepilone+in+ER%2FPR%2FHER2-negative+%28triple-negative%29+breast+cancer.&amp;publication_year=2010&amp;journal=Breast+Cancer+Res+Treat&amp;pages=261-271&amp;doi=10.1007%2Fs10549-010-0824-0&amp;pmid=20229176" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rates and short progression-free survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with survival rates in previous studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. <em>Breast Cancer Res Treat</em> 2012;133:1067-1075.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10549-012-2008-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22415477/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000305914900024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Second-line+bevacizumab-containing+therapy+in+patients+with+triple-negative+breast+cancer%3A+subgroup+analysis+of+the+RIBBON-2+trial.&amp;publication_year=2012&amp;journal=Breast+Cancer+Res+Treat&amp;pages=1067-1075&amp;doi=10.1007%2Fs10549-012-2008-6&amp;pmid=22415477" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rates and short progression-free survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with survival rates in previous studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Pivot X, Marmé F, Koenigsberg R, Guo M, Berrak E, Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. <em>Ann Oncol</em> 2016;27:1525-1531.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdw203" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27177860/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000383182800021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pooled+analyses+of+eribulin+in+metastatic+breast+cancer+patients+with+at+least+one+prior+chemotherapy.&amp;publication_year=2016&amp;journal=Ann+Oncol&amp;pages=1525-1531&amp;doi=10.1093%2Fannonc%2Fmdw203&amp;pmid=27177860" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rates and short progression-free survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with survival rates in previous studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Park IH, Im S-A, Jung KH, et al. Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: PROCEED trial (KCSG BR 11-01). <em>Cancer Res Treat</em> 2019;51:43-52.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4143/crt.2017.562" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29458237/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455439600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+open+label+phase+III+trial+of+irinotecan+plus+capecitabine+versus+capecitabine+monotherapy+in+patients+with+metastatic+breast+cancer+previously+treated+with+anthracycline+and+taxane%3A+PROCEED+trial+%28KCSG+BR+11-01%29.&amp;publication_year=2019&amp;journal=Cancer+Res+Treat&amp;pages=43-52&amp;doi=10.4143%2Fcrt.2017.562&amp;pmid=29458237" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rates and short progression-free survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with survival rates in previous studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Cortés J, Lipatov ON, Im S-A, et al. KEYNOTE-119: phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). <em>Ann Oncol</em> 2019;30:Suppl 5:v859-v860 (<a href="https://www.annalsofoncology.org/article/S0923-7534(19)60370-4/pdf">https://www.annalsofoncology.org/article/S0923-7534(19)60370-4/pdf</a>). abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=KEYNOTE-119%3A+phase+III+study+of+pembrolizumab+%28pembro%29+versus+single-agent+chemotherapy+%28chemo%29+for+metastatic+triple+negative+breast+cancer+%28mTNBC%29.&amp;publication_year=2019&amp;pages=v859-v860" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rates and short progression-free survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with survival rates in previous studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] median overall survival of 10.8 months). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). <em>Clin Cancer Res</em> 2001;7:2182-2194.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11489791/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000170328300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+pharmacokinetics+and+metabolism+of+irinotecan+%28CPT-11%29.&amp;publication_year=2001&amp;journal=Clin+Cancer+Res&amp;pages=2182-2194&amp;pmid=11489791" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Moon S-J, Govindan SV, Cardillo TM, D’Souza CA, Hansen HJ, Goldenberg DM. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. <em>J Med Chem</em> 2008;51:6916-6926.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1021/jm800719t" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18939816/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000260730900031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antibody+conjugates+of+7-ethyl-10-hydroxycamptothecin+%28SN-38%29+for+targeted+cancer+chemotherapy.&amp;publication_year=2008&amp;journal=J+Med+Chem&amp;pages=6916-6926&amp;doi=10.1021%2Fjm800719t&amp;pmid=18939816" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). <em>Oncotarget</em> 2015;6:22496-22512.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.18632/oncotarget.4318" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26101915/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Trop-2+is+a+novel+target+for+solid+cancer+therapy+with+sacituzumab+govitecan+%28IMMU-132%29%2C+an+antibody-drug+conjugate+%28ADC%29.&amp;publication_year=2015&amp;journal=Oncotarget&amp;pages=22496-22512&amp;doi=10.18632%2Foncotarget.4318&amp;pmid=26101915" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] through a proprietary hydrolyzable linker. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] targeted delivery of SN-38 to tumor cells. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] SN-38 release after internalization. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Ripani E, Sacchetti A, Corda D, Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. <em>Int J Cancer</em> 1998;76:671-676.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/(SICI)1097-0215(19980529)76:5%3C671::AID-IJC10%3E3.0.CO;2-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9610724/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000073774500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+Trop-2+is+a+tumor-associated+calcium+signal+transducer.&amp;publication_year=1998&amp;journal=Int+J+Cancer&amp;pages=671-676&amp;doi=10.1002%2F%28SICI%291097-0215%2819980529%2976%3A5%253C671%3A%3AAID-IJC10%253E3.0.CO%3B2-7&amp;pmid=9610724" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. <em>Onco Targets Ther</em> 2019;12:1781-1790.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/OTT.S162447" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30881031/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460074000003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+Trop-2+in+solid+tumors%3A+future+prospects.&amp;publication_year=2019&amp;journal=Onco+Targets+Ther&amp;pages=1781-1790&amp;doi=10.2147%2FOTT.S162447&amp;pmid=30881031" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] types, including breast cancer (&gt;90%). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] SN-38 release after internalization. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Basu A, Goldenberg DM, Stein R. The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. <em>Int J Cancer</em> 1995;62:472-479.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ijc.2910620419" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7635574/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1995RP81600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+epithelial%2Fcarcinoma+antigen+EGP-1%2C+recognized+by+monoclonal+antibody+RS7-3G11%2C+is+phosphorylated+on+serine+303.&amp;publication_year=1995&amp;journal=Int+J+Cancer&amp;pages=472-479&amp;doi=10.1002%2Fijc.2910620419&amp;pmid=7635574" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. <em>Clin Cancer Res</em> 2011;17:3157-3169.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-10-2939" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21372224/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000290610000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Humanized+anti-Trop-2+IgG-SN-38+conjugate+for+effective+treatment+of+diverse+epithelial+cancers%3A+preclinical+studies+in+human+cancer+xenograft+models+and+monkeys.&amp;publication_year=2011&amp;journal=Clin+Cancer+Res&amp;pages=3157-3169&amp;doi=10.1158%2F1078-0432.CCR-10-2939&amp;pmid=21372224" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). <em>Clin Cancer Res</em> 2015;21:5131-5138.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-15-0670" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26106073/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000364488700021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Enhanced+delivery+of+SN-38+to+human+tumor+xenografts+with+an+anti-Trop-2-SN-38+antibody+conjugate+%28sacituzumab+govitecan%29.&amp;publication_year=2015&amp;journal=Clin+Cancer+Res&amp;pages=5131-5138&amp;doi=10.1158%2F1078-0432.CCR-15-0670&amp;pmid=26106073" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. <em>J Hematol Oncol</em> 2021;14:20-20.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13045-021-01035-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33509252/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000613226600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antibody-drug+conjugates+in+solid+tumors%3A+a+look+into+novel+targets.&amp;publication_year=2021&amp;journal=J+Hematol+Oncol&amp;pages=20-20&amp;doi=10.1186%2Fs13045-021-01035-z&amp;pmid=33509252" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] SN-38 release after internalization. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] toxic effects with sacituzumab govitecan. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Trop-2–directed antibody–drug conjugate </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. <em>MAbs</em> 2019;11:987-995.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/19420862.2019.1632115" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31208270/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000478126200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antibody-drug+conjugates+targeting+TROP-2+and+incorporating+SN-38%3A+a+case+study+of+anti-TROP-2+sacituzumab+govitecan.&amp;publication_year=2019&amp;journal=MAbs&amp;pages=987-995&amp;doi=10.1080%2F19420862.2019.1632115&amp;pmid=31208270" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. <em>Bioconjug Chem</em> 2015;26:919-931.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1021/acs.bioconjchem.5b00223" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25915780/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000355053900015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sacituzumab+govitecan+%28IMMU-132%29%2C+an+anti-Trop-2%2FSN-38+antibody-drug+conjugate%3A+characterization+and+efficacy+in+pancreatic%2C+gastric%2C+and+other+cancers.&amp;publication_year=2015&amp;journal=Bioconjug+Chem&amp;pages=919-931&amp;doi=10.1021%2Facs.bioconjchem.5b00223&amp;pmid=25915780" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase 1/2 IMMU-132-01 basket trial. <em>Annal Oncol</em> 2021 March 16 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2021.03.005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33741442/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000648935000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sacituzumab+govitecan%2C+a+Trop-2%E2%80%93directed+antibody-drug+conjugate%2C+for+patients+with+epithelial+cancer%3A+final+safety+and+efficacy+results+from+the+phase+1%2F2+IMMU-132-01+basket+trial.&amp;publication_year=2021&amp;journal=Annal+Oncol&amp;doi=10.1016%2Fj.annonc.2021.03.005&amp;pmid=33741442" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. <em>J Clin Oncol</em> 2017;35:2141-2148.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.70.8297" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28291390/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404378800009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+anti-Trop-2+antibody+drug+conjugate+sacituzumab+govitecan+%28IMMU-132%29+in+heavily+pretreated+patients+with+metastatic+triple-negative+breast+cancer.&amp;publication_year=2017&amp;journal=J+Clin+Oncol&amp;pages=2141-2148&amp;doi=10.1200%2FJCO.2016.70.8297&amp;pmid=28291390" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. <em>N Engl J Med</em> 2019;380:741-751.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_24_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2028485&amp;key=10.1056%2FNEJMoa1814213&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30786188/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000459149500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sacituzumab+govitecan-hziy+in+refractory+metastatic+triple-negative+breast+cancer.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=741-751&amp;doi=10.1056%2FNEJMoa1814213&amp;pmid=30786188" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in metastatic, epithelial cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] was observed with sacituzumab govitecan. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] toxic effects with sacituzumab govitecan. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer. April 22, 2020 (<a href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sacituzumab-govitecan-hziy-metastatic-triple-negative-breast-cancer">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sacituzumab-govitecan-hziy-metastatic-triple-negative-breast-cancer</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=FDA+grants+accelerated+approval+to+sacituzumab+govitecan-hziy+for+metastatic+triple+negative+breast+cancer&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. <em>J Clin Oncol</em> 2010;28:2784-2795.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2009.25.6529" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20404251/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000278108800020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=American+Society+of+Clinical+Oncology%2FCollege+of+American+Pathologists+guideline+recommendations+for+immunohistochemical+testing+of+estrogen+and+progesterone+receptors+in+breast+cancer.&amp;publication_year=2010&amp;journal=J+Clin+Oncol&amp;pages=2784-2795&amp;doi=10.1200%2FJCO.2009.25.6529&amp;pmid=20404251" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). <em>Eur J Cancer</em> 2009;45:228-247.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ejca.2008.10.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19097774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000262948300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+response+evaluation+criteria+in+solid+tumours%3A+revised+RECIST+guideline+%28version+1.1%29.&amp;publication_year=2009&amp;journal=Eur+J+Cancer&amp;pages=228-247&amp;doi=10.1016%2Fj.ejca.2008.10.026&amp;pmid=19097774" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Twelves C, Cortes J, Vahdat L, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. <em>Breast Cancer Res Treat</em> 2014;148:553-561.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10549-014-3144-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25381136/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345370600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+eribulin+in+women+with+metastatic+breast+cancer%3A+a+pooled+analysis+of+two+phase+3+studies.&amp;publication_year=2014&amp;journal=Breast+Cancer+Res+Treat&amp;pages=553-561&amp;doi=10.1007%2Fs10549-014-3144-y&amp;pmid=25381136" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. <em>Ther Adv Med Oncol</em> 2020;12:1758835920915980-1758835920915980.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1758835920915980" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32426047/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000535757700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Novel+antibody-drug+conjugates+for+triple+negative+breast+cancer.&amp;publication_year=2020&amp;journal=Ther+Adv+Med+Oncol&amp;pages=1758835920915980-1758835920915980&amp;doi=10.1177%2F1758835920915980&amp;pmid=32426047" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Kadcyla (ado-trastuzumab emtansine). South San Francisco, CA: Genentech, 2019 (prescribing information).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r29-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Kadcyla+%28ado-trastuzumab+emtansine%29.+South+San+Francisco%2C+CA%3A+Genentech%2C+2019+%28prescribing+information%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r29-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r29-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Both ado-trastuzumab emtansine (T-DM1) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] associated with the cytotoxic component. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Enhertu (fam-trastuzumab deruxtecan-nxki). Basking Ridge, NJ: Daiichi Sankyo, December 2019 (prescribing information).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Enhertu+%28fam-trastuzumab+deruxtecan-nxki%29.+Basking+Ridge%2C+NJ%3A+Daiichi+Sankyo%2C+December+2019+%28prescribing+information%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. <em>Clin Cancer Res</em> 2016;22:5097-5108.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-15-2822" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27026201/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385632700018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DS-8201a%2C+a+novel+HER2-targeting+ADC+with+a+novel+DNA+topoisomerase+I+inhibitor%2C+demonstrates+a+promising+antitumor+efficacy+with+differentiation+from+T-DM1.&amp;publication_year=2016&amp;journal=Clin+Cancer+Res&amp;pages=5097-5108&amp;doi=10.1158%2F1078-0432.CCR-15-2822&amp;pmid=27026201" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 14, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2108478" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Sacituzumab Govitecan in Metastatic Breast Cancer</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Asheville, North Carolina</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/884050/hematology-medical-oncology-opportunity-in-asheville-area-western-north-carolina/?query=fjwp&amp;rid=19046">Hematology/Medical Oncology Opportunity in Asheville Area, Western North Carolina</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Hospitalist</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881587/hospitalist/?query=fjwp&amp;rid=165114">Hospitalist</a></div></div><div class="nejm-widget_item"><div><span> Weston, Florida</span></div><div><span>Pathology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891639/join-cleveland-clinic-florida-as-a-surgical-pathologist-in-weston-florida/?query=fjwf&amp;rid=2201">Join Cleveland Clinic Florida as a Surgical Pathologist in Weston, Florida</a></div></div><div class="nejm-widget_item"><div><span> Butte, Montana</span></div><div><span>Emergency Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881340/physician-emergency-medicine/?query=fjwf&amp;rid=751">Physician Emergency Medicine</a></div></div><div class="nejm-widget_item"><div><span> Sacramento, California</span></div><div><span>Urology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889182/physician-urology-sacramento-ca-/?query=fjwf&amp;rid=845679">Physician, Urology (Sacramento, CA)</a></div></div><div class="nejm-widget_item"><div><span> Apopka, Florida</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887563/primary-care-physician-im-or-fm-optum-apopka-fl/?query=fjwf&amp;rid=220874">Primary Care Physician (IM or FM) - Optum - Apopka, FL</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2028485&amp;pubId=41289464&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d67ae42361628a-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d67ae42361628a-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d67ae42361628a-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$317154018$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$317154018$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$317154018$--></div></div><div class="mlt-body"><!--?lit$317154018$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/case-records-of-the-massachusetts-general-hospital" target="_self"><!--?lit$317154018$-->Case Records of the Massachusetts General Hospital</a> <span class="mlt-article-site-label"><!--?lit$317154018$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$317154018$-->Jun 06, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMcpc2309499?query=recirc_Semantic" target="_self">Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer</a></div><div class="mlt-article-authors"><!--?lit$317154018$-->N. Vidula and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$317154018$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$317154018$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$317154018$-->Apr 03, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2405333?query=recirc_Semantic" target="_self">The Genetic Architecture of Congenital Diarrhea and Enteropathy</a></div><div class="mlt-article-authors"><!--?lit$317154018$-->Z. Gaibee and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$317154018$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$317154018$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$317154018$-->Jul 07, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2206661?query=recirc_Semantic" target="_self">DESTINY-Changing Results for Advanced Breast Cancer</a></div><div class="mlt-article-authors"><!--?lit$317154018$-->S.A. Hurvitz</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$317154018$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$317154018$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$317154018$-->Nov 28, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2409932?query=recirc_Semantic" target="_self">Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer</a></div><div class="mlt-article-authors"><!--?lit$317154018$-->P. Schmid and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$317154018$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$317154018$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$317154018$-->Jun 05, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2414859?query=recirc_Semantic" target="_self">Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy</a></div><div class="mlt-article-authors"><!--?lit$317154018$-->E.P. Mamounas and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2028485?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2028485" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2028485.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2028485"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2023294" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>A Microbiota-Directed Food Intervention for Undernourished Children</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMcp2031112" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Adrenal Incidentaloma</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028485_f1.jpg"><img src="/cms/10.1056/NEJMoa2028485/asset/ee77e7c3-1723-41ef-9d69-b22a916bc846/assets/images/large/nejmoa2028485_f1.jpg" height="2019" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Efficacy Results in Patients without Brain Metastases at Baseline and in the Full Population.</div><div class="notes"><div role="doc-footnote">Panels A and B show progression-free and overall survival, respectively, among patients without brain metastases. Progression-free survival was determined by blinded independent central review according to Response Evaluation Criteria in Solid Tumors, version 1.1. Panel C shows a waterfall plot of the best percent change in the sum of the diameters of target lesions in patients without brain metastases who had at least one response assessment by central review (212 patients in the sacituzumab govitecan group and 160 in the chemotherapy group). Asterisks at 0 denote patients who had no change from baseline in tumor size. Panel D shows progression-free survival among all randomly assigned patients (with or without brain metastases).</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028485_f2.jpg"><img src="/cms/10.1056/NEJMoa2028485/asset/e02a8b15-fcc3-4f89-812c-1bee96644cf7/assets/images/large/nejmoa2028485_f2.jpg" height="1808" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Subgroup Analysis of Progression-free Survival.</div><div class="notes"><div role="doc-footnote">NE denotes could not be evaluated, PD-1 programmed death 1, PD-L1 programmed death ligand 1, and TNBC triple-negative breast cancer.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Baseline Characteristics and Previous Treatment of Patients without Brain Metastases.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Summary of Treatment Efficacy, as Determined by Independent Central Review.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Summary of Treatment-Related Adverse Events in the Safety Population.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/384/16" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 384 No. 16</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 22, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2028700" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">I.O. Rosas and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 22, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2100433" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">The REMAP-CAP Investigators</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 22, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2023294" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">A Microbiota-Directed Food Intervention for Undernourished Children</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.Y. Chen and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2028485%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2028485&amp;pubId=41289464&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2028485%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2028485&amp;pubId=41289464&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id05116941619999756" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d67ae42361628a-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d67ae42361628a-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d67ae42361628a-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d67ae42361628a-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d67ae42361628a-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d67ae42361628a-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d67ae42361628a-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d67ae42361628a-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d67ae42361628a-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d67ae42361628a-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d67ae40a68628a',t:'MTc0OTUzMzQ2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d67ae40a68628a&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><dit-xepmafudaerj></dit-xepmafudaerj><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2028485?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><iframe name="captureIFrame_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-transactionid="v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" id="captureIFrame_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" target="captureIFrame_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="capture_screen"><input id="capture_signIn_js_version_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="js_version"><input id="capture_signIn_transactionId_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" type="hidden" class="capture_transactionId_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="capture_transactionId"><input id="capture_signIn_form_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="form"><input id="capture_signIn_flow_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="flow"><input id="capture_signIn_client_id_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="client_id"><input id="capture_signIn_redirect_uri_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="redirect_uri"><input id="capture_signIn_response_type_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="response_type"><input id="capture_signIn_flow_version_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="flow_version"><input id="capture_signIn_settings_version_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="settings_version"><input id="capture_signIn_locale_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="locale"><input id="capture_signIn_recaptcha_version_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_v8ege5o1exx4eut1kjzn55zxsra8yfo5wm6x3xey" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>